WO2006108666A1 - Mefloquine, nelfinavir et saquinavir utilises comme nouveaux agents dans les maladies neurodegeneratives et (neuro)inflammatoires - Google Patents
Mefloquine, nelfinavir et saquinavir utilises comme nouveaux agents dans les maladies neurodegeneratives et (neuro)inflammatoires Download PDFInfo
- Publication number
- WO2006108666A1 WO2006108666A1 PCT/EP2006/003437 EP2006003437W WO2006108666A1 WO 2006108666 A1 WO2006108666 A1 WO 2006108666A1 EP 2006003437 W EP2006003437 W EP 2006003437W WO 2006108666 A1 WO2006108666 A1 WO 2006108666A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- alkyl
- halo
- treatment
- hydrogen
- prevention
- Prior art date
Links
- XEEQGYMUWCZPDN-DOMZBBRYSA-N (-)-(11S,2'R)-erythro-mefloquine Chemical compound C([C@@H]1[C@@H](O)C=2C3=CC=CC(=C3N=C(C=2)C(F)(F)F)C(F)(F)F)CCCN1 XEEQGYMUWCZPDN-DOMZBBRYSA-N 0.000 title claims abstract description 60
- 229960001962 mefloquine Drugs 0.000 title claims abstract description 59
- QAGYKUNXZHXKMR-HKWSIXNMSA-N nelfinavir Chemical compound CC1=C(O)C=CC=C1C(=O)N[C@H]([C@H](O)CN1[C@@H](C[C@@H]2CCCC[C@@H]2C1)C(=O)NC(C)(C)C)CSC1=CC=CC=C1 QAGYKUNXZHXKMR-HKWSIXNMSA-N 0.000 title claims abstract description 47
- QAGYKUNXZHXKMR-UHFFFAOYSA-N CPD000469186 Natural products CC1=C(O)C=CC=C1C(=O)NC(C(O)CN1C(CC2CCCCC2C1)C(=O)NC(C)(C)C)CSC1=CC=CC=C1 QAGYKUNXZHXKMR-UHFFFAOYSA-N 0.000 title claims abstract description 45
- 229960000884 nelfinavir Drugs 0.000 title claims abstract description 45
- 229960001852 saquinavir Drugs 0.000 title claims abstract description 41
- QWAXKHKRTORLEM-UGJKXSETSA-N saquinavir Chemical compound C([C@@H]([C@H](O)CN1C[C@H]2CCCC[C@H]2C[C@H]1C(=O)NC(C)(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)C=1N=C2C=CC=CC2=CC=1)C1=CC=CC=C1 QWAXKHKRTORLEM-UGJKXSETSA-N 0.000 title claims abstract description 40
- 230000000626 neurodegenerative effect Effects 0.000 title claims abstract description 7
- 208000027866 inflammatory disease Diseases 0.000 title claims description 8
- 238000011282 treatment Methods 0.000 claims abstract description 54
- 230000002265 prevention Effects 0.000 claims abstract description 38
- 239000003814 drug Substances 0.000 claims abstract description 34
- 230000002757 inflammatory effect Effects 0.000 claims abstract description 31
- 230000002438 mitochondrial effect Effects 0.000 claims abstract description 18
- 208000036110 Neuroinflammatory disease Diseases 0.000 claims abstract description 5
- -1 acetyl mefloquine Chemical compound 0.000 claims description 76
- 125000000217 alkyl group Chemical group 0.000 claims description 70
- 150000001875 compounds Chemical class 0.000 claims description 70
- 229910052739 hydrogen Inorganic materials 0.000 claims description 46
- 239000001257 hydrogen Substances 0.000 claims description 45
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims description 42
- 230000000694 effects Effects 0.000 claims description 37
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 35
- 102100031156 Prohibitin-2 Human genes 0.000 claims description 27
- 229910052717 sulfur Inorganic materials 0.000 claims description 27
- 238000000034 method Methods 0.000 claims description 26
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 25
- 229910052760 oxygen Inorganic materials 0.000 claims description 24
- 238000004519 manufacturing process Methods 0.000 claims description 23
- 201000010099 disease Diseases 0.000 claims description 21
- 125000005843 halogen group Chemical group 0.000 claims description 20
- 230000001120 cytoprotective effect Effects 0.000 claims description 18
- 125000005842 heteroatom Chemical group 0.000 claims description 18
- 125000003118 aryl group Chemical group 0.000 claims description 17
- 125000004432 carbon atom Chemical group C* 0.000 claims description 17
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 17
- 239000000499 gel Substances 0.000 claims description 16
- 229910052757 nitrogen Inorganic materials 0.000 claims description 16
- 239000000243 solution Substances 0.000 claims description 16
- 125000003545 alkoxy group Chemical group 0.000 claims description 15
- 230000001640 apoptogenic effect Effects 0.000 claims description 14
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 14
- 208000035475 disorder Diseases 0.000 claims description 14
- 125000004415 heterocyclylalkyl group Chemical group 0.000 claims description 14
- 108010079245 Cystic Fibrosis Transmembrane Conductance Regulator Proteins 0.000 claims description 12
- 125000000623 heterocyclic group Chemical group 0.000 claims description 12
- 108090000353 Histone deacetylase Proteins 0.000 claims description 11
- 102000003964 Histone deacetylase Human genes 0.000 claims description 11
- 230000004054 inflammatory process Effects 0.000 claims description 11
- 208000010412 Glaucoma Diseases 0.000 claims description 10
- 206010025421 Macule Diseases 0.000 claims description 10
- 206010028980 Neoplasm Diseases 0.000 claims description 10
- 230000007850 degeneration Effects 0.000 claims description 10
- 239000003112 inhibitor Substances 0.000 claims description 10
- 230000000926 neurological effect Effects 0.000 claims description 10
- 150000003839 salts Chemical class 0.000 claims description 10
- 201000011510 cancer Diseases 0.000 claims description 9
- 230000003287 optical effect Effects 0.000 claims description 8
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 8
- 108091006146 Channels Proteins 0.000 claims description 7
- 208000002193 Pain Diseases 0.000 claims description 7
- 239000000725 suspension Substances 0.000 claims description 7
- 208000024827 Alzheimer disease Diseases 0.000 claims description 6
- 201000003883 Cystic fibrosis Diseases 0.000 claims description 6
- 230000001154 acute effect Effects 0.000 claims description 6
- 230000007423 decrease Effects 0.000 claims description 6
- 230000001771 impaired effect Effects 0.000 claims description 6
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 claims description 6
- 108010019625 Atazanavir Sulfate Proteins 0.000 claims description 5
- 206010012689 Diabetic retinopathy Diseases 0.000 claims description 5
- 206010061218 Inflammation Diseases 0.000 claims description 5
- KJHKTHWMRKYKJE-SUGCFTRWSA-N Kaletra Chemical compound N1([C@@H](C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC=2C=CC=CC=2)NC(=O)COC=2C(=CC=CC=2C)C)CC=2C=CC=CC=2)CCCNC1=O KJHKTHWMRKYKJE-SUGCFTRWSA-N 0.000 claims description 5
- 208000019695 Migraine disease Diseases 0.000 claims description 5
- 206010029240 Neuritis Diseases 0.000 claims description 5
- 208000022873 Ocular disease Diseases 0.000 claims description 5
- 208000007014 Retinitis pigmentosa Diseases 0.000 claims description 5
- 208000030886 Traumatic Brain injury Diseases 0.000 claims description 5
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims description 5
- 229960001830 amprenavir Drugs 0.000 claims description 5
- YMARZQAQMVYCKC-OEMFJLHTSA-N amprenavir Chemical compound C([C@@H]([C@H](O)CN(CC(C)C)S(=O)(=O)C=1C=CC(N)=CC=1)NC(=O)O[C@@H]1COCC1)C1=CC=CC=C1 YMARZQAQMVYCKC-OEMFJLHTSA-N 0.000 claims description 5
- 210000001367 artery Anatomy 0.000 claims description 5
- AXRYRYVKAWYZBR-GASGPIRDSA-N atazanavir Chemical compound C([C@H](NC(=O)[C@@H](NC(=O)OC)C(C)(C)C)[C@@H](O)CN(CC=1C=CC(=CC=1)C=1N=CC=CC=1)NC(=O)[C@@H](NC(=O)OC)C(C)(C)C)C1=CC=CC=C1 AXRYRYVKAWYZBR-GASGPIRDSA-N 0.000 claims description 5
- CBVCZFGXHXORBI-PXQQMZJSSA-N indinavir Chemical compound C([C@H](N(CC1)C[C@@H](O)C[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H]2C3=CC=CC=C3C[C@H]2O)C(=O)NC(C)(C)C)N1CC1=CC=CN=C1 CBVCZFGXHXORBI-PXQQMZJSSA-N 0.000 claims description 5
- 206010027599 migraine Diseases 0.000 claims description 5
- 201000006417 multiple sclerosis Diseases 0.000 claims description 5
- 208000015122 neurodegenerative disease Diseases 0.000 claims description 5
- 201000001119 neuropathy Diseases 0.000 claims description 5
- 230000007823 neuropathy Effects 0.000 claims description 5
- 208000033808 peripheral neuropathy Diseases 0.000 claims description 5
- NCDNCNXCDXHOMX-XGKFQTDJSA-N ritonavir Chemical compound N([C@@H](C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1SC=NC=1)CC=1C=CC=CC=1)C(=O)N(C)CC1=CSC(C(C)C)=N1 NCDNCNXCDXHOMX-XGKFQTDJSA-N 0.000 claims description 5
- 230000009529 traumatic brain injury Effects 0.000 claims description 5
- WHTVZRBIWZFKQO-AWEZNQCLSA-N (S)-chloroquine Chemical compound ClC1=CC=C2C(N[C@@H](C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-AWEZNQCLSA-N 0.000 claims description 4
- 208000018737 Parkinson disease Diseases 0.000 claims description 4
- 208000006011 Stroke Diseases 0.000 claims description 4
- 125000004183 alkoxy alkyl group Chemical group 0.000 claims description 4
- 125000003282 alkyl amino group Chemical group 0.000 claims description 4
- 125000004103 aminoalkyl group Chemical group 0.000 claims description 4
- 125000005098 aryl alkoxy carbonyl group Chemical group 0.000 claims description 4
- 125000005129 aryl carbonyl group Chemical group 0.000 claims description 4
- 125000004391 aryl sulfonyl group Chemical group 0.000 claims description 4
- 229910052799 carbon Inorganic materials 0.000 claims description 4
- 229960003677 chloroquine Drugs 0.000 claims description 4
- WHTVZRBIWZFKQO-UHFFFAOYSA-N chloroquine Natural products ClC1=CC=C2C(NC(C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-UHFFFAOYSA-N 0.000 claims description 4
- 125000003709 fluoroalkyl group Chemical group 0.000 claims description 4
- 229910052736 halogen Inorganic materials 0.000 claims description 4
- 150000002367 halogens Chemical group 0.000 claims description 4
- 125000006517 heterocyclyl carbonyl group Chemical group 0.000 claims description 4
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims description 4
- 201000010901 lateral sclerosis Diseases 0.000 claims description 4
- 208000005264 motor neuron disease Diseases 0.000 claims description 4
- 150000002895 organic esters Chemical class 0.000 claims description 4
- 239000008194 pharmaceutical composition Substances 0.000 claims description 4
- 239000011148 porous material Substances 0.000 claims description 4
- 230000007704 transition Effects 0.000 claims description 4
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 claims description 3
- AXRYRYVKAWYZBR-UHFFFAOYSA-N Atazanavir Natural products C=1C=C(C=2N=CC=CC=2)C=CC=1CN(NC(=O)C(NC(=O)OC)C(C)(C)C)CC(O)C(NC(=O)C(NC(=O)OC)C(C)(C)C)CC1=CC=CC=C1 AXRYRYVKAWYZBR-UHFFFAOYSA-N 0.000 claims description 3
- 208000023275 Autoimmune disease Diseases 0.000 claims description 3
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims description 3
- 208000019693 Lung disease Diseases 0.000 claims description 3
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 3
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 claims description 3
- 206010039085 Rhinitis allergic Diseases 0.000 claims description 3
- NCDNCNXCDXHOMX-UHFFFAOYSA-N Ritonavir Natural products C=1C=CC=CC=1CC(NC(=O)OCC=1SC=NC=1)C(O)CC(CC=1C=CC=CC=1)NC(=O)C(C(C)C)NC(=O)N(C)CC1=CSC(C(C)C)=N1 NCDNCNXCDXHOMX-UHFFFAOYSA-N 0.000 claims description 3
- 206010040047 Sepsis Diseases 0.000 claims description 3
- 208000025865 Ulcer Diseases 0.000 claims description 3
- 206010069351 acute lung injury Diseases 0.000 claims description 3
- 201000000028 adult respiratory distress syndrome Diseases 0.000 claims description 3
- 125000003342 alkenyl group Chemical group 0.000 claims description 3
- 125000004448 alkyl carbonyl group Chemical group 0.000 claims description 3
- 125000004390 alkyl sulfonyl group Chemical group 0.000 claims description 3
- 201000010105 allergic rhinitis Diseases 0.000 claims description 3
- 208000006673 asthma Diseases 0.000 claims description 3
- 229960003277 atazanavir Drugs 0.000 claims description 3
- 125000006254 cycloalkyl carbonyl group Chemical group 0.000 claims description 3
- 210000005095 gastrointestinal system Anatomy 0.000 claims description 3
- 230000002068 genetic effect Effects 0.000 claims description 3
- 229960001936 indinavir Drugs 0.000 claims description 3
- 230000004968 inflammatory condition Effects 0.000 claims description 3
- 229960004525 lopinavir Drugs 0.000 claims description 3
- 201000005202 lung cancer Diseases 0.000 claims description 3
- 208000020816 lung neoplasm Diseases 0.000 claims description 3
- 230000004065 mitochondrial dysfunction Effects 0.000 claims description 3
- 230000002314 neuroinflammatory effect Effects 0.000 claims description 3
- 230000001575 pathological effect Effects 0.000 claims description 3
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 3
- 229960000311 ritonavir Drugs 0.000 claims description 3
- 229920006395 saturated elastomer Polymers 0.000 claims description 3
- 239000007921 spray Substances 0.000 claims description 3
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims description 3
- OVCDSSHSILBFBN-UHFFFAOYSA-N Amodiaquine Chemical compound C1=C(O)C(CN(CC)CC)=CC(NC=2C3=CC=C(Cl)C=C3N=CC=2)=C1 OVCDSSHSILBFBN-UHFFFAOYSA-N 0.000 claims description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 2
- 239000002671 adjuvant Substances 0.000 claims description 2
- 125000000304 alkynyl group Chemical group 0.000 claims description 2
- 229960001444 amodiaquine Drugs 0.000 claims description 2
- 125000005099 aryl alkyl carbonyl group Chemical group 0.000 claims description 2
- 239000002775 capsule Substances 0.000 claims description 2
- 125000002837 carbocyclic group Chemical group 0.000 claims description 2
- 239000003085 diluting agent Substances 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 125000004356 hydroxy functional group Chemical group O* 0.000 claims description 2
- 239000011505 plaster Substances 0.000 claims description 2
- 208000023504 respiratory system disease Diseases 0.000 claims description 2
- 239000003826 tablet Substances 0.000 claims description 2
- 102000012605 Cystic Fibrosis Transmembrane Conductance Regulator Human genes 0.000 claims 8
- 239000007922 nasal spray Substances 0.000 claims 1
- 229940097496 nasal spray Drugs 0.000 claims 1
- 230000000324 neuroprotective effect Effects 0.000 abstract description 26
- 102000016670 prohibitin Human genes 0.000 abstract description 23
- 108010028138 prohibitin Proteins 0.000 abstract description 23
- 108010038795 estrogen receptors Proteins 0.000 abstract description 8
- 102000015694 estrogen receptors Human genes 0.000 abstract description 8
- 230000003993 interaction Effects 0.000 abstract description 7
- 230000002424 anti-apoptotic effect Effects 0.000 abstract description 6
- 230000005764 inhibitory process Effects 0.000 abstract description 5
- 230000003110 anti-inflammatory effect Effects 0.000 abstract description 4
- 108010022133 Voltage-Dependent Anion Channel 1 Proteins 0.000 abstract description 2
- 102000012290 Voltage-Dependent Anion Channel 1 Human genes 0.000 abstract description 2
- 210000004027 cell Anatomy 0.000 description 54
- 239000000126 substance Substances 0.000 description 30
- 108090000623 proteins and genes Proteins 0.000 description 27
- 101710098058 Prohibitin-2 Proteins 0.000 description 26
- 102100037820 Voltage-dependent anion-selective channel protein 1 Human genes 0.000 description 26
- 108050001627 Voltage-dependent anion-selective channel protein 1 Proteins 0.000 description 26
- 102000004169 proteins and genes Human genes 0.000 description 23
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 20
- 239000002158 endotoxin Substances 0.000 description 20
- 229920006008 lipopolysaccharide Polymers 0.000 description 20
- 229920002684 Sepharose Polymers 0.000 description 16
- 238000001262 western blot Methods 0.000 description 15
- 102000007272 Apoptosis Inducing Factor Human genes 0.000 description 14
- 108010033604 Apoptosis Inducing Factor Proteins 0.000 description 14
- 101150071146 COX2 gene Proteins 0.000 description 14
- 101100114534 Caenorhabditis elegans ctc-2 gene Proteins 0.000 description 14
- 102100029438 Nitric oxide synthase, inducible Human genes 0.000 description 14
- 101710089543 Nitric oxide synthase, inducible Proteins 0.000 description 14
- 101150000187 PTGS2 gene Proteins 0.000 description 14
- 150000002632 lipids Chemical group 0.000 description 14
- 238000010186 staining Methods 0.000 description 14
- 230000001413 cellular effect Effects 0.000 description 12
- 238000010790 dilution Methods 0.000 description 12
- 239000012895 dilution Substances 0.000 description 12
- 230000009471 action Effects 0.000 description 11
- 230000007246 mechanism Effects 0.000 description 11
- 230000001964 calcium overload Effects 0.000 description 10
- 210000001671 embryonic stem cell Anatomy 0.000 description 10
- 208000028867 ischemia Diseases 0.000 description 10
- 238000004949 mass spectrometry Methods 0.000 description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 10
- 239000011324 bead Substances 0.000 description 9
- 238000003556 assay Methods 0.000 description 8
- 230000015572 biosynthetic process Effects 0.000 description 8
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 8
- 229940079593 drug Drugs 0.000 description 8
- 238000002474 experimental method Methods 0.000 description 8
- 239000000284 extract Substances 0.000 description 8
- 230000014509 gene expression Effects 0.000 description 8
- 230000000638 stimulation Effects 0.000 description 8
- 238000003786 synthesis reaction Methods 0.000 description 8
- IRHXGOXEBNJUSN-YOXDLBRISA-N Saquinavir mesylate Chemical compound CS(O)(=O)=O.C([C@@H]([C@H](O)CN1C[C@H]2CCCC[C@H]2C[C@H]1C(=O)NC(C)(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)C=1N=C2C=CC=CC2=CC=1)C1=CC=CC=C1 IRHXGOXEBNJUSN-YOXDLBRISA-N 0.000 description 7
- 239000003795 chemical substances by application Substances 0.000 description 7
- 229940011871 estrogen Drugs 0.000 description 7
- 239000000262 estrogen Substances 0.000 description 7
- 230000001537 neural effect Effects 0.000 description 7
- 230000004112 neuroprotection Effects 0.000 description 7
- 230000000861 pro-apoptotic effect Effects 0.000 description 7
- 230000004083 survival effect Effects 0.000 description 7
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 6
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 6
- 229920000776 Poly(Adenosine diphosphate-ribose) polymerase Polymers 0.000 description 6
- 206010044221 Toxic encephalopathy Diseases 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 6
- 239000011575 calcium Substances 0.000 description 6
- 229910052791 calcium Inorganic materials 0.000 description 6
- 239000003153 chemical reaction reagent Substances 0.000 description 6
- 238000001514 detection method Methods 0.000 description 6
- 238000011161 development Methods 0.000 description 6
- 231100000318 excitotoxic Toxicity 0.000 description 6
- 230000003492 excitotoxic effect Effects 0.000 description 6
- 125000001072 heteroaryl group Chemical group 0.000 description 6
- 230000006698 induction Effects 0.000 description 6
- 238000005259 measurement Methods 0.000 description 6
- 230000001404 mediated effect Effects 0.000 description 6
- 239000012528 membrane Substances 0.000 description 6
- 210000002569 neuron Anatomy 0.000 description 6
- 239000001301 oxygen Substances 0.000 description 6
- 125000004434 sulfur atom Chemical group 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 108010090849 Amyloid beta-Peptides Proteins 0.000 description 5
- 102000013455 Amyloid beta-Peptides Human genes 0.000 description 5
- 206010029350 Neurotoxicity Diseases 0.000 description 5
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 230000001419 dependent effect Effects 0.000 description 5
- 230000018109 developmental process Effects 0.000 description 5
- 238000001914 filtration Methods 0.000 description 5
- 238000005194 fractionation Methods 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 238000003384 imaging method Methods 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 230000016273 neuron death Effects 0.000 description 5
- 230000007135 neurotoxicity Effects 0.000 description 5
- 231100000228 neurotoxicity Toxicity 0.000 description 5
- 125000004430 oxygen atom Chemical group O* 0.000 description 5
- 239000004215 Carbon black (E152) Substances 0.000 description 4
- 102100023419 Cystic fibrosis transmembrane conductance regulator Human genes 0.000 description 4
- 241000588724 Escherichia coli Species 0.000 description 4
- 241000282414 Homo sapiens Species 0.000 description 4
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 4
- 108010053229 Lysyl endopeptidase Proteins 0.000 description 4
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- 241000283973 Oryctolagus cuniculus Species 0.000 description 4
- 102000016611 Proteoglycans Human genes 0.000 description 4
- 108010067787 Proteoglycans Proteins 0.000 description 4
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 4
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 4
- 239000000427 antigen Substances 0.000 description 4
- 108091007433 antigens Proteins 0.000 description 4
- 102000036639 antigens Human genes 0.000 description 4
- 230000006907 apoptotic process Effects 0.000 description 4
- 238000003149 assay kit Methods 0.000 description 4
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 4
- 239000000460 chlorine Substances 0.000 description 4
- 235000012000 cholesterol Nutrition 0.000 description 4
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 4
- UKWLRLAKGMZXJC-QIECWBMSSA-L disodium;[4-chloro-3-[(3r,5s)-1-chloro-3'-methoxyspiro[adamantane-4,4'-dioxetane]-3'-yl]phenyl] phosphate Chemical compound [Na+].[Na+].O1OC2([C@@H]3CC4C[C@H]2CC(Cl)(C4)C3)C1(OC)C1=CC(OP([O-])([O-])=O)=CC=C1Cl UKWLRLAKGMZXJC-QIECWBMSSA-L 0.000 description 4
- 239000000328 estrogen antagonist Substances 0.000 description 4
- 210000002950 fibroblast Anatomy 0.000 description 4
- 229930195712 glutamate Natural products 0.000 description 4
- 239000004030 hiv protease inhibitor Substances 0.000 description 4
- 229930195733 hydrocarbon Natural products 0.000 description 4
- 238000012744 immunostaining Methods 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 238000002955 isolation Methods 0.000 description 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 4
- 230000037361 pathway Effects 0.000 description 4
- 102000013415 peroxidase activity proteins Human genes 0.000 description 4
- 108040007629 peroxidase activity proteins Proteins 0.000 description 4
- 239000002953 phosphate buffered saline Substances 0.000 description 4
- 229920002401 polyacrylamide Polymers 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 230000000770 proinflammatory effect Effects 0.000 description 4
- 239000013014 purified material Substances 0.000 description 4
- 238000012113 quantitative test Methods 0.000 description 4
- 229910052709 silver Inorganic materials 0.000 description 4
- 239000004332 silver Substances 0.000 description 4
- HEMHJVSKTPXQMS-UHFFFAOYSA-M sodium hydroxide Inorganic materials [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 4
- 239000003656 tris buffered saline Substances 0.000 description 4
- 125000006163 5-membered heteroaryl group Chemical group 0.000 description 3
- 206010006187 Breast cancer Diseases 0.000 description 3
- 208000026310 Breast neoplasm Diseases 0.000 description 3
- 102000003893 Histone acetyltransferases Human genes 0.000 description 3
- 108090000246 Histone acetyltransferases Proteins 0.000 description 3
- SJRJJKPEHAURKC-UHFFFAOYSA-N N-Methylmorpholine Chemical compound CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 description 3
- 108010064218 Poly (ADP-Ribose) Polymerase-1 Proteins 0.000 description 3
- 102100023712 Poly [ADP-ribose] polymerase 1 Human genes 0.000 description 3
- 101150054344 Smarca4 gene Proteins 0.000 description 3
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 3
- 102000040945 Transcription factor Human genes 0.000 description 3
- 108091023040 Transcription factor Proteins 0.000 description 3
- 108090001129 Voltage-dependent anion channels Proteins 0.000 description 3
- 102000004962 Voltage-dependent anion channels Human genes 0.000 description 3
- 101710202136 Voltage-dependent anion-selective channel Proteins 0.000 description 3
- 230000002411 adverse Effects 0.000 description 3
- VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 3
- 108010064397 amyloid beta-protein (1-40) Proteins 0.000 description 3
- FEWOUVRMGWFWIH-ILZZQXMPSA-N amyloid-beta polypeptide 40 Chemical compound C([C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)NCC(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(O)=O)[C@@H](C)CC)C(C)C)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C(C)C)C1=CC=CC=C1 FEWOUVRMGWFWIH-ILZZQXMPSA-N 0.000 description 3
- 150000001450 anions Chemical class 0.000 description 3
- 210000004556 brain Anatomy 0.000 description 3
- 150000001768 cations Chemical class 0.000 description 3
- 230000030833 cell death Effects 0.000 description 3
- 231100000433 cytotoxic Toxicity 0.000 description 3
- 230000001472 cytotoxic effect Effects 0.000 description 3
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 3
- 230000000302 ischemic effect Effects 0.000 description 3
- 239000003550 marker Substances 0.000 description 3
- 230000010534 mechanism of action Effects 0.000 description 3
- 125000002950 monocyclic group Chemical group 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 239000011593 sulfur Substances 0.000 description 3
- 125000001305 1,2,4-triazol-3-yl group Chemical group [H]N1N=C([*])N=C1[H] 0.000 description 2
- 125000006218 1-ethylbutyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])[H] 0.000 description 2
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- 125000000389 2-pyrrolyl group Chemical group [H]N1C([*])=C([H])C([H])=C1[H] 0.000 description 2
- UMCMPZBLKLEWAF-BCTGSCMUSA-N 3-[(3-cholamidopropyl)dimethylammonio]propane-1-sulfonate Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCCC[N+](C)(C)CCCS([O-])(=O)=O)C)[C@@]2(C)[C@@H](O)C1 UMCMPZBLKLEWAF-BCTGSCMUSA-N 0.000 description 2
- 125000001397 3-pyrrolyl group Chemical group [H]N1C([H])=C([*])C([H])=C1[H] 0.000 description 2
- SKDHHIUENRGTHK-UHFFFAOYSA-N 4-nitrobenzoyl chloride Chemical compound [O-][N+](=O)C1=CC=C(C(Cl)=O)C=C1 SKDHHIUENRGTHK-UHFFFAOYSA-N 0.000 description 2
- QRXMUCSWCMTJGU-UHFFFAOYSA-N 5-bromo-4-chloro-3-indolyl phosphate Chemical compound C1=C(Br)C(Cl)=C2C(OP(O)(=O)O)=CNC2=C1 QRXMUCSWCMTJGU-UHFFFAOYSA-N 0.000 description 2
- 108091005978 ADP-ribosylated proteins Proteins 0.000 description 2
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 2
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 2
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 241000283707 Capra Species 0.000 description 2
- 208000002177 Cataract Diseases 0.000 description 2
- 108020004635 Complementary DNA Proteins 0.000 description 2
- 108010037462 Cyclooxygenase 2 Proteins 0.000 description 2
- 102100030497 Cytochrome c Human genes 0.000 description 2
- 108010075031 Cytochromes c Proteins 0.000 description 2
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- 102000003974 Fibroblast growth factor 2 Human genes 0.000 description 2
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 229920002971 Heparan sulfate Polymers 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 101001129610 Homo sapiens Prohibitin 1 Proteins 0.000 description 2
- 101000805450 Homo sapiens Voltage-dependent anion-selective channel protein 1 Proteins 0.000 description 2
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 2
- 239000007836 KH2PO4 Substances 0.000 description 2
- WESWYMRNZNDGBX-YLCXCWDSSA-N Mefloquine hydrochloride Chemical compound Cl.C([C@@H]1[C@@H](O)C=2C3=CC=CC(=C3N=C(C=2)C(F)(F)F)C(F)(F)F)CCCN1 WESWYMRNZNDGBX-YLCXCWDSSA-N 0.000 description 2
- 102000018697 Membrane Proteins Human genes 0.000 description 2
- 108010052285 Membrane Proteins Proteins 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- 101000654471 Mus musculus NAD-dependent protein deacetylase sirtuin-1 Proteins 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- HOKKHZGPKSLGJE-GSVOUGTGSA-N N-Methyl-D-aspartic acid Chemical compound CN[C@@H](C(O)=O)CC(O)=O HOKKHZGPKSLGJE-GSVOUGTGSA-N 0.000 description 2
- 239000000020 Nitrocellulose Substances 0.000 description 2
- 101150056105 PHB1 gene Proteins 0.000 description 2
- 241000223960 Plasmodium falciparum Species 0.000 description 2
- 229920001213 Polysorbate 20 Polymers 0.000 description 2
- 102100038280 Prostaglandin G/H synthase 2 Human genes 0.000 description 2
- 108010029485 Protein Isoforms Proteins 0.000 description 2
- 102000001708 Protein Isoforms Human genes 0.000 description 2
- 108010026552 Proteome Proteins 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 101710172711 Structural protein Proteins 0.000 description 2
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 2
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 2
- 102000004243 Tubulin Human genes 0.000 description 2
- 108090000704 Tubulin Proteins 0.000 description 2
- 241000269368 Xenopus laevis Species 0.000 description 2
- 230000001594 aberrant effect Effects 0.000 description 2
- 230000021736 acetylation Effects 0.000 description 2
- 238000006640 acetylation reaction Methods 0.000 description 2
- 125000003277 amino group Chemical group 0.000 description 2
- 238000004873 anchoring Methods 0.000 description 2
- 239000003430 antimalarial agent Substances 0.000 description 2
- 230000009925 apoptotic mechanism Effects 0.000 description 2
- 239000000090 biomarker Substances 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- SNCZNSNPXMPCGN-UHFFFAOYSA-N butanediamide Chemical compound NC(=O)CCC(N)=O SNCZNSNPXMPCGN-UHFFFAOYSA-N 0.000 description 2
- 239000004202 carbamide Substances 0.000 description 2
- 150000001721 carbon Chemical group 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 239000013592 cell lysate Substances 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- 238000002038 chemiluminescence detection Methods 0.000 description 2
- 229910052801 chlorine Inorganic materials 0.000 description 2
- 208000022371 chronic pain syndrome Diseases 0.000 description 2
- 229940088900 crixivan Drugs 0.000 description 2
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 2
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 2
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 2
- 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 2
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 2
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 2
- 230000001086 cytosolic effect Effects 0.000 description 2
- 230000006196 deacetylation Effects 0.000 description 2
- 238000003381 deacetylation reaction Methods 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 230000009977 dual effect Effects 0.000 description 2
- 238000010828 elution Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 230000005284 excitation Effects 0.000 description 2
- 229910052731 fluorine Inorganic materials 0.000 description 2
- 239000012737 fresh medium Substances 0.000 description 2
- 238000011990 functional testing Methods 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 238000013537 high throughput screening Methods 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 108091008147 housekeeping proteins Proteins 0.000 description 2
- 230000002209 hydrophobic effect Effects 0.000 description 2
- 238000010874 in vitro model Methods 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 230000037456 inflammatory mechanism Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 229940088976 invirase Drugs 0.000 description 2
- PGHMRUGBZOYCAA-ADZNBVRBSA-N ionomycin Chemical compound O1[C@H](C[C@H](O)[C@H](C)[C@H](O)[C@H](C)/C=C/C[C@@H](C)C[C@@H](C)C(/O)=C/C(=O)[C@@H](C)C[C@@H](C)C[C@@H](CCC(O)=O)C)CC[C@@]1(C)[C@@H]1O[C@](C)([C@@H](C)O)CC1 PGHMRUGBZOYCAA-ADZNBVRBSA-N 0.000 description 2
- PGHMRUGBZOYCAA-UHFFFAOYSA-N ionomycin Natural products O1C(CC(O)C(C)C(O)C(C)C=CCC(C)CC(C)C(O)=CC(=O)C(C)CC(C)CC(CCC(O)=O)C)CCC1(C)C1OC(C)(C(C)O)CC1 PGHMRUGBZOYCAA-UHFFFAOYSA-N 0.000 description 2
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- 229940112586 kaletra Drugs 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 2
- 238000001840 matrix-assisted laser desorption--ionisation time-of-flight mass spectrometry Methods 0.000 description 2
- DZNKOAWEHDKBEP-UHFFFAOYSA-N methyl 2-[6-[bis(2-methoxy-2-oxoethyl)amino]-5-[2-[2-[bis(2-methoxy-2-oxoethyl)amino]-5-methylphenoxy]ethoxy]-1-benzofuran-2-yl]-1,3-oxazole-5-carboxylate Chemical compound COC(=O)CN(CC(=O)OC)C1=CC=C(C)C=C1OCCOC(C(=C1)N(CC(=O)OC)CC(=O)OC)=CC2=C1OC(C=1OC(=CN=1)C(=O)OC)=C2 DZNKOAWEHDKBEP-UHFFFAOYSA-N 0.000 description 2
- 210000004925 microvascular endothelial cell Anatomy 0.000 description 2
- 235000013336 milk Nutrition 0.000 description 2
- 239000008267 milk Substances 0.000 description 2
- 210000004080 milk Anatomy 0.000 description 2
- 210000003470 mitochondria Anatomy 0.000 description 2
- 210000001700 mitochondrial membrane Anatomy 0.000 description 2
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 2
- 230000000877 morphologic effect Effects 0.000 description 2
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- 210000000653 nervous system Anatomy 0.000 description 2
- 230000004770 neurodegeneration Effects 0.000 description 2
- 230000006764 neuronal dysfunction Effects 0.000 description 2
- 230000003961 neuronal insult Effects 0.000 description 2
- 230000002887 neurotoxic effect Effects 0.000 description 2
- 229920001220 nitrocellulos Polymers 0.000 description 2
- 229940072250 norvir Drugs 0.000 description 2
- 238000011275 oncology therapy Methods 0.000 description 2
- 210000000287 oocyte Anatomy 0.000 description 2
- 238000005457 optimization Methods 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 230000010412 perfusion Effects 0.000 description 2
- 239000002831 pharmacologic agent Substances 0.000 description 2
- 101150090473 phb-2 gene Proteins 0.000 description 2
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 2
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 2
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 2
- 229920000136 polysorbate Polymers 0.000 description 2
- GNSKLFRGEWLPPA-UHFFFAOYSA-M potassium dihydrogen phosphate Chemical compound [K+].OP(O)([O-])=O GNSKLFRGEWLPPA-UHFFFAOYSA-M 0.000 description 2
- 238000011533 pre-incubation Methods 0.000 description 2
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 230000004224 protection Effects 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 238000011002 quantification Methods 0.000 description 2
- 230000000284 resting effect Effects 0.000 description 2
- 229940107904 reyataz Drugs 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- 230000019491 signal transduction Effects 0.000 description 2
- 235000020183 skimmed milk Nutrition 0.000 description 2
- LPXPTNMVRIOKMN-UHFFFAOYSA-M sodium nitrite Chemical compound [Na+].[O-]N=O LPXPTNMVRIOKMN-UHFFFAOYSA-M 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 230000001052 transient effect Effects 0.000 description 2
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 description 1
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 description 1
- 125000005919 1,2,2-trimethylpropyl group Chemical group 0.000 description 1
- 125000001766 1,2,4-oxadiazol-3-yl group Chemical group [H]C1=NC(*)=NO1 0.000 description 1
- 125000004505 1,2,4-oxadiazol-5-yl group Chemical group O1N=CN=C1* 0.000 description 1
- 125000004515 1,2,4-thiadiazol-3-yl group Chemical group S1N=C(N=C1)* 0.000 description 1
- 125000004516 1,2,4-thiadiazol-5-yl group Chemical group S1N=CN=C1* 0.000 description 1
- 125000004509 1,3,4-oxadiazol-2-yl group Chemical group O1C(=NN=C1)* 0.000 description 1
- 125000004521 1,3,4-thiadiazol-2-yl group Chemical group S1C(=NN=C1)* 0.000 description 1
- 125000004317 1,3,5-triazin-2-yl group Chemical group [H]C1=NC(*)=NC([H])=N1 0.000 description 1
- 125000006017 1-propenyl group Chemical group 0.000 description 1
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 1
- SVUOLADPCWQTTE-UHFFFAOYSA-N 1h-1,2-benzodiazepine Chemical compound N1N=CC=CC2=CC=CC=C12 SVUOLADPCWQTTE-UHFFFAOYSA-N 0.000 description 1
- 125000006176 2-ethylbutyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(C([H])([H])*)C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000002941 2-furyl group Chemical group O1C([*])=C([H])C([H])=C1[H] 0.000 description 1
- 125000004493 2-methylbut-1-yl group Chemical group CC(C*)CC 0.000 description 1
- 125000005916 2-methylpentyl group Chemical group 0.000 description 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
- 125000000175 2-thienyl group Chemical group S1C([*])=C([H])C([H])=C1[H] 0.000 description 1
- 125000003682 3-furyl group Chemical group O1C([H])=C([*])C([H])=C1[H] 0.000 description 1
- 125000003542 3-methylbutan-2-yl group Chemical group [H]C([H])([H])C([H])(*)C([H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000005917 3-methylpentyl group Chemical group 0.000 description 1
- 125000001541 3-thienyl group Chemical group S1C([H])=C([*])C([H])=C1[H] 0.000 description 1
- KDDQRKBRJSGMQE-UHFFFAOYSA-N 4-thiazolyl Chemical group [C]1=CSC=N1 KDDQRKBRJSGMQE-UHFFFAOYSA-N 0.000 description 1
- CWDWFSXUQODZGW-UHFFFAOYSA-N 5-thiazolyl Chemical group [C]1=CN=CS1 CWDWFSXUQODZGW-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- 102100033350 ATP-dependent translocase ABCB1 Human genes 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 206010001022 Acute psychosis Diseases 0.000 description 1
- 229940123702 Adenosine A2a receptor antagonist Drugs 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 description 1
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 description 1
- 101100422770 Caenorhabditis elegans sup-1 gene Proteins 0.000 description 1
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- 102000011045 Chloride Channels Human genes 0.000 description 1
- 108010062745 Chloride Channels Proteins 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 108010077544 Chromatin Proteins 0.000 description 1
- 208000000094 Chronic Pain Diseases 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 206010010305 Confusional state Diseases 0.000 description 1
- 102000010970 Connexin Human genes 0.000 description 1
- 108050001175 Connexin Proteins 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- 101710108485 Envelope phospholipase F13 Proteins 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- 208000001914 Fragile X syndrome Diseases 0.000 description 1
- 206010053759 Growth retardation Diseases 0.000 description 1
- 208000031886 HIV Infections Diseases 0.000 description 1
- 208000037357 HIV infectious disease Diseases 0.000 description 1
- 102100039869 Histone H2B type F-S Human genes 0.000 description 1
- 102100039996 Histone deacetylase 1 Human genes 0.000 description 1
- 102100021453 Histone deacetylase 5 Human genes 0.000 description 1
- 108010033040 Histones Proteins 0.000 description 1
- 101001035372 Homo sapiens Histone H2B type F-S Proteins 0.000 description 1
- 101001035024 Homo sapiens Histone deacetylase 1 Proteins 0.000 description 1
- 101000899255 Homo sapiens Histone deacetylase 5 Proteins 0.000 description 1
- 101000950695 Homo sapiens Mitogen-activated protein kinase 8 Proteins 0.000 description 1
- 241000725303 Human immunodeficiency virus Species 0.000 description 1
- 208000023105 Huntington disease Diseases 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-L L-tartrate(2-) Chemical compound [O-]C(=O)[C@H](O)[C@@H](O)C([O-])=O FEWJPZIEWOKRBE-JCYAYHJZSA-L 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- 102000043136 MAP kinase family Human genes 0.000 description 1
- 108091054455 MAP kinase family Proteins 0.000 description 1
- 108010047230 Member 1 Subfamily B ATP Binding Cassette Transporter Proteins 0.000 description 1
- 102000006404 Mitochondrial Proteins Human genes 0.000 description 1
- 108010058682 Mitochondrial Proteins Proteins 0.000 description 1
- 102100037808 Mitogen-activated protein kinase 8 Human genes 0.000 description 1
- 208000019022 Mood disease Diseases 0.000 description 1
- 208000016285 Movement disease Diseases 0.000 description 1
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 208000008457 Neurologic Manifestations Diseases 0.000 description 1
- 208000025966 Neurological disease Diseases 0.000 description 1
- 208000007125 Neurotoxicity Syndromes Diseases 0.000 description 1
- 102000004966 Nuclear Receptor Coactivator 1 Human genes 0.000 description 1
- 108090001146 Nuclear Receptor Coactivator 1 Proteins 0.000 description 1
- 108700020796 Oncogene Proteins 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 208000037273 Pathologic Processes Diseases 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 1
- 102000000033 Purinergic Receptors Human genes 0.000 description 1
- 108010080192 Purinergic Receptors Proteins 0.000 description 1
- 108091027981 Response element Proteins 0.000 description 1
- 206010039281 Rubinstein-Taybi syndrome Diseases 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- AUYYCJSJGJYCDS-LBPRGKRZSA-N Thyrolar Chemical class IC1=CC(C[C@H](N)C(O)=O)=CC(I)=C1OC1=CC=C(O)C(I)=C1 AUYYCJSJGJYCDS-LBPRGKRZSA-N 0.000 description 1
- 231100000076 Toxic encephalopathy Toxicity 0.000 description 1
- 108010040002 Tumor Suppressor Proteins Proteins 0.000 description 1
- 102000001742 Tumor Suppressor Proteins Human genes 0.000 description 1
- KPCZJLGGXRGYIE-UHFFFAOYSA-N [C]1=CC=CN=C1 Chemical group [C]1=CC=CN=C1 KPCZJLGGXRGYIE-UHFFFAOYSA-N 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 108091005764 adaptor proteins Proteins 0.000 description 1
- 102000035181 adaptor proteins Human genes 0.000 description 1
- 239000002467 adenosine A2a receptor antagonist Substances 0.000 description 1
- 210000001789 adipocyte Anatomy 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O ammonium group Chemical group [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 1
- 150000001449 anionic compounds Chemical class 0.000 description 1
- 230000003178 anti-diabetic effect Effects 0.000 description 1
- 229940046836 anti-estrogen Drugs 0.000 description 1
- 230000001833 anti-estrogenic effect Effects 0.000 description 1
- 230000000078 anti-malarial effect Effects 0.000 description 1
- 230000003579 anti-obesity Effects 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 238000011394 anticancer treatment Methods 0.000 description 1
- 239000003472 antidiabetic agent Substances 0.000 description 1
- 229940111121 antirheumatic drug quinolines Drugs 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 229940127225 asthma medication Drugs 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 1
- 229940049706 benzodiazepine Drugs 0.000 description 1
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 108091008324 binding proteins Proteins 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 230000004094 calcium homeostasis Effects 0.000 description 1
- 230000006369 cell cycle progression Effects 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000023715 cellular developmental process Effects 0.000 description 1
- 230000004637 cellular stress Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 210000002932 cholinergic neuron Anatomy 0.000 description 1
- 210000003483 chromatin Anatomy 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000000875 corresponding effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 229940088679 drug related substance Drugs 0.000 description 1
- 239000003596 drug target Substances 0.000 description 1
- 229940125436 dual inhibitor Drugs 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 229960005309 estradiol Drugs 0.000 description 1
- 229930182833 estradiol Natural products 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 125000004612 furopyridinyl group Chemical group O1C(=CC2=C1C=CC=N2)* 0.000 description 1
- 210000003976 gap junction Anatomy 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 1
- 125000001183 hydrocarbyl group Chemical group 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
- 230000001146 hypoxic effect Effects 0.000 description 1
- 125000004857 imidazopyridinyl group Chemical group N1C(=NC2=C1C=CC=N2)* 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 description 1
- 125000001041 indolyl group Chemical group 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 108091006086 inhibitor proteins Proteins 0.000 description 1
- 229910001412 inorganic anion Inorganic materials 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 125000001977 isobenzofuranyl group Chemical group C=1(OC=C2C=CC=CC12)* 0.000 description 1
- 125000005990 isobenzothienyl group Chemical group 0.000 description 1
- 125000004491 isohexyl group Chemical group C(CCC(C)C)* 0.000 description 1
- 125000000904 isoindolyl group Chemical group C=1(NC=C2C=CC=CC12)* 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 201000004792 malaria Diseases 0.000 description 1
- 238000013507 mapping Methods 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 229960005329 mefloquine hydrochloride Drugs 0.000 description 1
- 210000002284 membrane microdomain Anatomy 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 239000003607 modifier Substances 0.000 description 1
- 230000009456 molecular mechanism Effects 0.000 description 1
- 125000002757 morpholinyl group Chemical group 0.000 description 1
- 210000002161 motor neuron Anatomy 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000003136 n-heptyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 208000004296 neuralgia Diseases 0.000 description 1
- 230000003227 neuromodulating effect Effects 0.000 description 1
- 208000021722 neuropathic pain Diseases 0.000 description 1
- 231100000189 neurotoxic Toxicity 0.000 description 1
- 239000002581 neurotoxin Substances 0.000 description 1
- 230000030648 nucleus localization Effects 0.000 description 1
- 150000002891 organic anions Chemical class 0.000 description 1
- 150000002892 organic cations Chemical class 0.000 description 1
- 230000009054 pathological process Effects 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 125000005561 phenanthryl group Chemical group 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 125000003386 piperidinyl group Chemical group 0.000 description 1
- 230000023603 positive regulation of transcription initiation, DNA-dependent Effects 0.000 description 1
- 239000011736 potassium bicarbonate Substances 0.000 description 1
- 229910000028 potassium bicarbonate Inorganic materials 0.000 description 1
- TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 230000004853 protein function Effects 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 229940121374 purinergic receptor antagonist Drugs 0.000 description 1
- 125000004307 pyrazin-2-yl group Chemical group [H]C1=C([H])N=C(*)C([H])=N1 0.000 description 1
- 125000002206 pyridazin-3-yl group Chemical group [H]C1=C([H])C([H])=C(*)N=N1 0.000 description 1
- 125000004940 pyridazin-4-yl group Chemical group N1=NC=C(C=C1)* 0.000 description 1
- 125000000246 pyrimidin-2-yl group Chemical group [H]C1=NC(*)=NC([H])=C1[H] 0.000 description 1
- 125000004527 pyrimidin-4-yl group Chemical group N1=CN=C(C=C1)* 0.000 description 1
- 125000004528 pyrimidin-5-yl group Chemical group N1=CN=CC(=C1)* 0.000 description 1
- 150000003248 quinolines Chemical class 0.000 description 1
- 229910052704 radon Inorganic materials 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 230000007115 recruitment Effects 0.000 description 1
- 230000016914 response to endoplasmic reticulum stress Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000011808 rodent model Methods 0.000 description 1
- 229960003542 saquinavir mesylate Drugs 0.000 description 1
- 125000003548 sec-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 230000009758 senescence Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- JVBXVOWTABLYPX-UHFFFAOYSA-L sodium dithionite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])=O JVBXVOWTABLYPX-UHFFFAOYSA-L 0.000 description 1
- 235000010288 sodium nitrite Nutrition 0.000 description 1
- 230000000707 stereoselective effect Effects 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 229960001603 tamoxifen Drugs 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 125000001973 tert-pentyl group Chemical group [H]C([H])([H])C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 239000005495 thyroid hormone Substances 0.000 description 1
- 229940036555 thyroid hormone Drugs 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 229940023080 viracept Drugs 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Definitions
- Mefloquine, Nelfinavir and Saquinavir as novel agents for neurodegenerative and (neuro-) inflammatory diseases
- the present invention generally relates to the neuroprotective, anti-apoptotic and anti-inflammatory activity of mefloquine, nelfinavir and saquinavir and derivatives thereof based on recently discovered interactions with prohibitin and estrogen receptors and the inhibition of mitochondrial voltage- dependent anion channel 1.
- mefloquine, nelfinavir and saquinavir and derivatives thereof may be used as medicaments for the prevention and/or treatment of neurodegenerative and inflammatory, particularly neuroinflammatory diseases.
- Nelfinavir (Viracept ® ) and saquinavir (Invirase ® or Fortovase ® ) are known as anti-HI V drugs called HIV protease inhibitors.
- Further HIV protease inhibitors of the same class of compounds are amprenavir (Agenerase ® ), indinavir (Crixivan ® ), lopinavir (Kaletra ® ), ritonavir (Norvir ® ) and atazanavir (Reyataz ® ). These compounds are used for treatment of HIV.
- Nelfinavir is usually administered in the form of (3S-(2(2S*,3S*), 3 ⁇ ,4a ⁇ ,8a ⁇ ))-N-(1 , 1 -dimethylethyl)decahydro-2-(2-hydroxy-3-((3-hydroxy-2- methylbenzoyl)amino)-4-(phenylthio)butyl)-3-isoquinolinecarboxamide;
- the compound, its manufacture, its mechanism of action and its clinical efficacy have been described in the state of the art.
- Saquinavir is usually administered in the form of Saquinavir mesylate (S)-N- (( ⁇ SJ- ⁇ -CCIR ⁇ -CCSS ⁇ aS. ⁇ aSJ-a-Ctert-butylcarbamoyOoctahydro ⁇ CI H)- isoquinolyl)-1 -hydroxyethyl) phenethyl)-2-quinaldamidosuccinamide mono- methanesulfonate (salt); DRG-0164; Fortovase ® ; Invirase ® ; Ro 31-8959/003; Saquinavir monomethanesulfonate salt; butanediamide, N(sup 1)-(3-(3- (((1 ,1 -dimethylethyl)amino) carbonyl)octahydro-2(1 H)-isoquinolinyl)-2- hydroxy-1- (phenylmethyl)propyl)-2-((2-quinoliny
- Mefloquine (Lariam ® ) is known as an anti-malaria drug which has high efficacy in treating the widespread chloroquine-resistant Plasmodium falciparum strains. Mefloquine is used both for prophylaxis and treatment of malaria and is relatively well tolerated.
- Mefloquine is usually administered in the form of mefloquine hydrochloride CR*, S?)-(+-)- ⁇ -2- piperidinyl-2, 8-bis (trifluoromethyl)-4-quinolinemethanol- monohydrochloride; DL-erythro- ⁇ -2-piperidyl-2,8-bis(trifluoromethyl)-4- quinolinemethanol monohydrochloride; WR-142490; Ro-21-5998; Lariam ® . Ci 7 Hi 7 CIF 6 N 2 O; mol wt 414.78. C 49.23%, H 4.13%, Cl 8.55%, F 27.48%, N 6.75%, O 3.86%.
- the relatively new antimalarial mefloquine (Lariam ® ) has become extremely popular due to its efficacy in treating the wide-spread chloroquine-resistant Plasmodium falciparum strains. Mefloquine is known both for severe neurologic and psychiatric adverse effects associated with its use.
- the crucial molecular features correlated with neurotoxicity are under investigation and certain molecular features defining neurotoxicity are emerging.
- VDA1 voltage-dependent anion selective channel-1
- VDAC voltage dependent anion selective channel
- VDAC proteins are tyrosine-phosphorylated under hypoxic conditions suggesting that tyrosine phosphorylation may then contribute to the modulation of VDAC protein function/conformation or interaction with other proteins (Liberatori S. et al., Proteomics 4, 1335-1340 (2004)). Also a role as redox sensor has been suggested recently (Baker M. A. et al., Biofactors 21, 215-221 (2004)). This relates very well to the experimental examples described below.
- Prohibitins comprise a remarkably conserved protein family in eukaryotic cells with proposed functions in cell cycle progression, cancer, cellular stress management, senescence, apoptosis, and the regulation of mitochondrial activities (Liu H. et al., Proteomics 10, 3167-3176 (2004); Huang C. M. et al., Mass Spectrom. Rev. (2004); Wang K. J. et al., World of Gastroenterol. 10, 2179-2183, (2004); Wang S. et al. EMBO J. 23, 2293-2303 (2004); Gamble S. C. et al., Oncogene 23, 2996-3004 (2004); Joshi B. et al. Biochem. Biophys. Res. Commun.
- Phb1 and Phb2 Two prohibitin homologues, Phb1 and Phb2, assemble into a high molecular weight complex of approximately 1.2 MDa in the mitochondrial inner membrane, but a nuclear localization of Phb1 and Phb2 also has been reported (Tatsuta T. et al., MoI. Biol. Cell. 16, 248- 259, (2005)).
- Prohibitin is also a tumor suppressor enriched in membrane microdomains, called lipid rafts and associated with viral infectious and inflammatory pathways, potentially via mitogen-activated protein kinase (e.g. Sharma A. et al., Proc. Natl. Acad. Sci. USA 101, 17492-17497 (2004)).
- estrogen may exert neuroprotective effects against ⁇ -amyloid-induced toxicity by activation of estrogen receptor-mediated pathways in cholinergic neurons as a model for the pathology of Alzheimer's disease.
- intracellular estrogen receptors are up-regulated by their cognate hormone even during exposure to neurotoxic agents, like ⁇ - amyloid1-40 (Marin R. et al., Neuroscience 121, 917-926 (2003)).
- Estrogen appears to be an important neuromodulatory molecule.
- REA repressor of estrogen receptor activity
- REA is recruited to the hormone-occupied ER 1 decreases the transcriptional activity of ER, both when ER is acting directly through DNA response elements as well as when it is tethered to other transcription factors.
- Estrogen antagonists are universally employed in the breast cancer therapy.
- the molecular mechanisms by which these agents inhibit cellular proliferation in breast cancer cells are not fully defined.
- E2F family of transcription factors
- E2F repressor like prohibitin and the chromatin modifiers Brg1/Brm are required for estrogen antagonist-mediated growth suppression through the estrogen receptor, and that their recruitment to native promoter-bound E2F is induced via a JNK1 pathway.
- HATs histone acetyltransferases
- HDACs histone deacetylases
- Histone acetyltransferases and deacetylases are recruited by transcription factors and adapter proteins to regulate specific subsets of target genes.
- the repressor of estrogen receptor activity (REA) has been identified as a novel HDAC1 -associated protein. REA also associates with the class Il histone deacetylase HDAC5 (Kurtev V. et al., J. Biol. Chem 279, 24834- 24843, (2004)).
- Estrogen and REA also appear to play a role in pathological processes in the eye: Despite the high prevalence of age-related cataracts, there are currently no known therapies to delay or prevent their occurrence. Studies in humans and rodent models suggest that estrogen may provide protection against age-related cataracts. The discovery of ocular estrogen receptors
- estrogens indicates that estrogen protection may result from direct interactions with its receptors in the eye, instead an indirect consequence from effects on another tissue.
- mefloquine, nelfinavir and saquinavir and related compounds interact with prohibitin and estrogen receptor repressor (REA) and inhibit VDAC-1. Based on these results it is demonstrated that mefloquine, nelfinavir and saquinavir and related compounds have cytoprotective and particularly neuro-protective efficacy.
- REA estrogen receptor repressor
- mefloquine, nelfinavir and saquinavir and related compounds are suitable for the prevention and/or treatment of diseases which are caused by, associated with or accompanied by calcium overload and inflammatory and/or apoptotic events.
- a first aspect of the present invention relates to the use of a compound of formulae (1), (2), (3), (4) or (5)
- cytoprotective medicament particularly a medicament for the prevention or treatment of a disease associated with an inflammatory component, e.g. a neurological or non-neurological inflammatory disease.
- an inflammatory component e.g. a neurological or non-neurological inflammatory disease.
- Ri, R 2 and R 4 are independently from each other hydrogen, Ci-C 6 -(halo)alkyl, or C3-C 8 -(halo)cycloalkyl, wherein the alkyl or cycloalkyl group is optionally substituted with a five- or six-membered ring optionally containing at least one heteroatom selected from N, S and O, and wherein the ring is optionally monosubstituted up to polysubstituted with halo, Ci-C 4 -(halo)alkyl, CrC 4 -(halo)alkoxy, amino, Ci-C 4 - alkylamino, di(Ci-C 4 -alkyl)amino or Z, wherein Z is a Ci-C 6 -(halo)alkyl group (D-su bstituted with a group -NR 5 R 6 , wherein R 5 and R 6 are independently from each other hydrogen, Ci-C 8 -alkyl, or CO-d
- R 3 is hydrogen, C 1 -C 6 -(halo)alkyl, C 3 -C 8 -(halo)cycloalkyl, or -NR 7 R 8 wherein R 7 and R 8 are independently from each other hydrogen, Ci-C 8 -alkyl, or
- R 7 and R 8 together form a five- or six- membered ring optionally containing at least one further heteroatom selected from N 1 S and O 1 wherein the ring is optionally monosubstituted up to polysubstituted with halo, C 1 -C 4 -(halo)alkyl and Ci-C 4 -(halo)alkoxy.
- Ri is hydrogen, Ci-C 6 -(halo)alkyl, or C 3 -C 8 -(halo)cycloalkyl, wherein the alkyl or cycloalkyl group is optionally substituted with a five- or six- membered ring optionally containing at least one heteroatom selected from N, S and O, and wherein the ring is optionally mono- or polysubstituted with halo, Ci-C 4 -(halo)alkyl, Ci-C 4 -(halo)alkoxy, amino, Ci- C 4 -alkylamino, di(d-C 4 -alkyl)amino or Z, wherein Z is a Ci-C 6 -(halo) alkyl group ⁇ -substituted with a group -NR 7 Re, wherein R 7 and R 8 are independently from each other hydrogen, Ci-C ⁇ -alkyI, or CO-Ci-C 8 -alkyl or wherein R 7 and R 8 together form
- R 2 is hydrogen, halogen, Ci-C 6 -(halo)alkyl, or C 3 -C ⁇ -(halo)cycloalkyl, -NR9R10, wherein R 9 and R10 are independently from each other hydrogen, Ci-C ⁇ -alkyI, or CO-Ci-C 8 -alkyl or wherein R 9 and R10 together form a five- or six-membered ring optionally containing at least one further heteroatom selected from N, S and O, wherein the ring is optionally monosubstituted up to polysubstituted with halo, CrC 4 -(halo) alkyl and Ci-C 4 -(halo)alkoxy,
- R 3 is hydrogen, Ci-C 6 -(halo)alkyl, or C 3 -C 8 -(halo)cycloalkyl, halogen, ORn, wherein Rn is d-C 6 -(halo)alkyl, or C 3 -C 8 -(halo)cycloalkyl,
- R 4 is hydrogen, Ci-C 6 -(halo)alkyl, or C 3 -C 8 -(halo)cycloalkyl, CO-C r C 8 -alkyl,
- R 5 is hydrogen, CrC 6 -(halo)alkyl, C 3 -C 8 -(halo)cycloalkyl or CO-Ci-C 8 -alkyl and
- R 6 is hydrogen, Ci-C 6 -(halo)alkyl, C 3 -C 8 -(halo)cycloalkyl or C 2 -C 6 -alkylnyl.
- Ri is hydrogen, hydroxy or NHR 2 ,
- R 2 is hydrogen, alkyl, alkenyl, alkynyl, arylalkyl, heterocyclylalkyl, cycloalkyl, alkylcarbonyl, cycloalkylcarbonyl, arylcarbonyl, heterocyclylcarbonyl, arylalkylcarbonyl, heterocyclylalkylcarbonyl, alkoxycarbonyl, arylalkyl oxycarbonyl, heterocyclylalkoxycarbonyl, aryl, heterocyclyl, sulfonyl, alkylsulfonyl, arylsulfonyl, heterocyclylsulfonyl or a group of the formula
- R 7 and R 8 are independently from each other hydrogen, alkyl, aryl, heterocyclyl, arylalkyl, heterocyclyl alkyl or
- R 7 and R 8 together with the nitrogen atom to which they are attached form a saturated ring optionally containing a further heteroatom or a group
- R 3 , R 4 are independently from each other hydrogen, alkyl, carbamido, or R 3 , R 4 form together with the carbon atom to which they are attached a carbocyclic ring,
- R 5 is hydrogen or the residue of an inorganic or an organic ester and R 6 is alkyl, arylalkyl, heterocyclylalkyl, alkyloxyalkyl, hydroxyalkyl, amino alkyl, fluoroalkyl and Ri 3 is aryl, ⁇ -alkylaryl, ⁇ -alkylarylether or co-alkylarylthioether.
- Ri is alkyl, arylalkyl, heterocyclylalkyl, alkoxyalkyl, hydroxyalkyl, alkylamino, aminoalkyl, fluoroalkyl,
- R 2 is hydrogen or the residue of an inorganic or an organic ester
- R 3 is aryl, ⁇ -alkylaryl, ⁇ -alkylaryl ether or ⁇ -alkylaryl thioether and R 4 is aryl.
- the compounds of formulae (1), (2) and (3) and its pharmaceutically acceptable salts may be prepared as described in the citations indicated in the Merck Index, 12 th edition, 1996 (cf. citations indicated on page 3 to 4).
- Halo is, for example, fluorine, chlorine, bromine or iodine.
- alkyl is related to saturated, straight-chain or branched hydrocarbon radicals having 1 to 4, 5, 6, 8, 9 or 10 carbon atoms, e.g. C 1 -C 6 alkyl such as methyl, ethyl, propyl, 1-methylethyl, butyl, 1- methylpropyl, 2-methylpropyl, 1,1-dimethylethyl, pentyl, 1 -methyl butyl, 2- methylbutyl, 3-methylbutyl, 2,2-dimethylpropyl, 1-ethylbutyl, hexyl, 1 ,1- dimethylpropyl, 1 ,2- dimethylpropyl, 1-methylpentyl, 2-methylpentyl, 3- methylpentyl, 4-methylpentyl, 1 ,1-dimethylbutyl, 1-ethylbutyl, 2-ethylbutyl,
- Ci-C ⁇ -alkyl is, for example, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, n-pentyl, neopentyl, n-hexyl, n-heptyl or n-octyl, preferably Ci-C 4 -alkyl, especially methyl or ethyl, and more especially methyl.
- ,Alkylcarbonyl are straight-chain or branched alkyl groups having 1 to 10 carbon atoms (as mentioned above), which are bonded to the structure via a carbonyl group (-CO-).
- Alkylsulfonyl are straight-chain or branched alkyl groups having 1 to 10 carbon atoms (as mentioned above), which are bonded to the structure via a sulfonyl group (-SO 2 ).
- alkenyl are unsaturated, straight-chain or branched hydrocarbon radicals having 2 to 10 carbon atoms and a double bond in any desired position, e.g. C 2 -C 6 -alkenyl such as ethenyl, 1-propenyl, 2-propenyl.
- Alkylnyl are straight-chain or branched hydrocarbon groups having 2 to 10 carbon atoms and a triple bond in any desired position, e.g. C 2 -C 6 -alkynyl.
- alkyl are straight-chain or branched alkyl group having 1 to 4 carbon atoms (as mentioned above) which are optionally substituted by at least one halo, substituent up to perhalogenation.
- ,Alkoxy are straight-chain or branched alkyl groups having 1 to 10 or 1 to 10 carbon atoms (as mentioned above), which are bonded to the structure via an oxygen atom (-O-).
- alkoxycarbonyl are straight-chain or branched alkoxy groups having 1 to 10 carbon atoms (as mentioned above), which are bonded to the structure via a carbonyl group (-CO-).
- ..Cycloalkyl are monocyclic alkyl groups having 3 to 12 carbon ring members, e.g. C 3 -C B -cycloalkyl such as cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl and cyclooctyl.
- Cycloalkylcarbonyl is a monocyclic alkyl group having 3 to 12, e.g. 3 to 6, 8 to 12 carbon ring members (as mentioned above), which is bonded to the structure via a carbonyl group (-CO-).
- C 3 -C 8 -(Halo)cycloalky1 are monocyclic alkyl groups with 3 to 8 carbon ring members, eg. C 3 -C 8 -cycloalkyl such as cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl and cyclooctyl which are optionally substituted by at least one halo substitutent up to perhalogenation.
- Ci-C 4 -(Halo)alkoxy are straight-chain or linear alkyl groups with 1 to 4, carbon atoms which are bound to the structure by an oxygen atom (-O-) and which are optionally substituted by at least one halo substitutent up to perhalogenation.
- Alkylamino are straight-chain or branched alkyl groups with 1 to 4 carbon atoms, which are bound to the structure by an amino group (-NH-).
- Ci-C4-Alkylamino or "di(Ci-C 4 )alkylamino” are straight-chain or branched alkyl groups with 1 to 4 carbon atoms, which are bound to the structure by an amino group (-NH-) or by the nitrogen atom (-N:) respectively.
- Aryl or arylalkyl, arylsulfonyl, arylcarbonyl and arylalkoxycarbonyl are aromatic mono- or polycyclic hydrocarbon radicals which are bonded to the structure directly or (arylalkyl) via an alkyl group, (arylsulfonyl) via a sulfonyl group (-SO 2 -), (arylcarbonyl) via a carbonyl group (-CO-) and (arylalkoxycarbonyl) via an alkoxycarbonyl group, e.g. phenyl, naphthyl and phenanthryl and the corresponding radicals.
- Heterocyclyl is a five- or six-membered ring optionally containing at least one heteroatom selected from N, S and O.
- a five- or six-membered ring optionally containing at least one heteroatom selected from N, S and O may be for example: a 5-membered heteroaryl, containing one to three nitrogen atoms: 5- membered ring heteroaryl groups, which in addition to carbon atoms can contain one to three nitrogen atoms as ring members, eg. 2-pyrrolyl, 3- pyrrolyl, 3-pyrazolyl, 4-pyrazolyl, 5-pyrazolyl, 2-imidazolyl, 4-imidazolyl, 1 ,2,4-triazol-3-yl and 1 ,3,4-triazol-2-yl;
- 5-membered heteroaryl containing one to four nitrogen atoms or one to three nitrogen atoms and a sulfur or oxygen atom or an oxygen or a sulfur atom
- 5-membered ring heteroaryl groups which in addition to carbon atoms can contain one to four nitrogen atoms or one to three nitrogen atoms and a sulfur or oxygen atom or an oxygen or sulfur atom as ring members, eg.
- 5-membered ring heteroaryl groups which in addition to carbon atoms can contain one to four nitrogen atoms or one to three nitrogen atoms and a sulfur or oxygen atom or an oxygen or a sulfur atom as ring members, and in which two adjacent carbon ring members or a nitrogen and an adjacent carbon ring member can be bridged to form an aromatic or heteroaromatic bicycle or polycycle, eg.
- 6-membered heteroaryl containing one to three or one to four nitrogen atoms: 6-membered ring heteroaryl groups, which in addition to carbon atoms can contain one to three or one to four nitrogen atoms as ring members, eg. 2-pyridinyl, 3-pyridinyl, 4-pyridinyl, 3-pyridazinyl, 4-pyridazinyl, 2-pyrimidinyl, 4-pyrimidinyl, 5-pyrimidinyl, 2-pyrazinyl, 1 ,3,5-triazin-2-yl, 1 ,2,4-triazin-3-yl and 1 ,2,4,5-tetrazin-3-yl; or
- an aliphatic heterocyclyl such as piperidinyl and morpholinyl.
- Heterocyclylalkyl, Heterocyclylsulfonyl, Heterocyclylcarbonyl and Heterocyclylalkoxycarbonyl are aromatic mono- or polycyclic hydrocarbon radicals which in addition to carbon ring members additionally can contain one to four nitrogen atoms or one to three nitrogen atoms and an oxygen or a sulfur atom or an oxygen or a sulfur atom and which are bonded to the structure (heterocyclylalkyl) via an alkyl group, (heterocyclylsulfonyl) via a sulfonyl group (-SO 2 -), (heterocyclylcarbonyl) via a carbonyl group (-CO-), and (heterocyclylalkoxycarbonyl) via an alkoxycarbonyl group.
- the compounds of formulae (1), (2), (3), (4) and (5) may be present as an optical enantiomer or diastereomer or any mixture of enantiomers, such as racemates, or diastereomers.
- ,salt preferably refers to pharmaceutically acceptable salts of compounds of formulae (1), (2), (3), (4) and (5) with suitable cations and/or anions.
- suitable cations are alkaline metal cations such as Li + ; Na + and K + , alkaline earth metal cations such as Mg 2+ and Ca 2+ as well as suitable organic cations, e.g. ammoniums or substituted ammonium cations.
- pharmaceutically acceptable anions are inorganic anions such as chloride, sulfate, hydrogensulfate, phosphate or organic anions such as acetate, citrate, tartrate, etc.
- Derivatives of the compounds of formulae (1), (2), (3), (4) and (5) are any molecules which are converted under physiological conditions to a compound of formulae (1 ), (2), (3), (4) and (5) respectively, e.g. esters, amides etc. of compounds of formulae (1), (2), (3), (4) and (5) molecules which are products of metabolization reactions of a any compound of formulae (1 ), (2), (3), (4) and (5).
- Preferred examples of the compounds of formulae (1), (2) and (3) include mefloquine and derivatives thereof, e.g. acetyl mefloquine, chloroquine, quenine, primquine, ablaquine and amodiaquine as well as derivatives thereof.
- Preferred examples of the compounds of formulae (4) and (5) include nelfinavir/saquinavir and derivatives thereof, e.g. amprenavir (Agenerase ® ), indinavir (Crixivan ® ), lopinavir (Kaletra ® ), ritonavir (Norvir ® ) and atazanavir (Reyataz ® ).
- the compounds of formulae (1) to (5) are used for the prevention or treatment of disorders associated with apoptotic or neuroinflammatory, or generally inflammatory disorders which are caused by and/or accompanied by mitochondrial dysfunction, particularly a dysfunctional mitochondrial transition pore, and/or disorders which are caused by and/or accompanied by HDAC-dysfunction, particularly a dysfunctional decrease in HDAC activity.
- these disorders include neurodegenerative or neuroinflammatory diseases or pathological conditions, like M. Alzheimer, traumatic brain injury, M. Parkinson, amytrophic lateral sclerosis (ALS), stroke, migraine and multiple sclerosis.
- At least one of the common lung diseases associated with a significant inflammatory component such as severe sepsis, acute lung injury, acute respiratory distress syndrome, cystic fibrosis, asthma, allergic rhinitis, or COPD or lung cancer, as well as any other cancer type.
- a further preferred indication is the prevention or treatment of cystic fibrosis, particularly in persons with impaired function of the cystic fibrosis transmembrane conductance regulator (CFTR) Cl " channel or the prevention or treatment of ulcerative or other inflammatory conditions of the gastrointestinal system, particularly of persons with impaired function of the cystic fibrosis transmembrane conductance regulator (CFTR) Cl " channel.
- CFTR cystic fibrosis transmembrane conductance regulator
- Still a further preferred indication is for the prevention or treatment of inflammatory processes involved in cancer prevention or progression.
- Still a further preferred indication is for the prevention or treatment of inflammatory processes involved in autoimmune diseases such as rheumatoid arthritis or systemic lupus erythematosus, especially for the treatment of patients identified by genetic or other markers to be more likely to be especially amenable to such treatment.
- autoimmune diseases such as rheumatoid arthritis or systemic lupus erythematosus
- a further preferred indication is for the prevention or treatment of inflammatory or inflammation-associated ocular disorders, particularly macula degeneration, e.g. moist or dry macula degeneration, glaucoma, e.g. acute, primary, secondary or low angle glaucoma, diabetic retinopathy, anterior or posterior optical neuropathy, retinitis pigmentosa, neuritis nervi optici, or central artery obstruction.
- macula degeneration e.g. moist or dry macula degeneration
- glaucoma e.g. acute, primary, secondary or low angle glaucoma
- diabetic retinopathy e.g. acute, primary, secondary or low angle glaucoma
- anterior or posterior optical neuropathy retinitis pigmentosa
- neuritis nervi optici e.g. central artery obstruction.
- a further aspect of the present invention relates to the use of a compound which is a MTP or REA inhibitor/modulator for the manufacture of a medicament for the prevention or treatment of airway diseases, preferably for the prevention or treatment of disorders as indicated above.
- the compounds of formulae (1) to (5) may be used alone or together with other medicaments, e.g. oral asthma medications, antidiabetic or anticancer treatments.
- the dual inhibitor compound is preferably a moderately strong VDAC-1 inhibitor, which has an IC 50 value for VDAC from 100 to 10000 ⁇ M, more preferably from 250 to 1000 ⁇ M.
- the determination of the IC 50 value is carried out as indicated as in the Examples.
- a further aspect of the present invention relates to the use of a compound which is a dual VDAC-1 /REA inhibitor or binding protein for the manufacture of a neuro- or cytoprotective medicament, preferably for the prevention or treatment of disorders as indicated above.
- the compound is preferably a moderately strong VDAC-1 inhibitor as indicated above.
- the IC 50 value is from 1 to 10,000 ⁇ M, more preferably from 5 to 1 ,000 ⁇ M. The determination of the IC 50 value is carried out as indicated in the Examples.
- the compounds as indicated above are preferably administered to a subject in need thereof as a pharmaceutical composition, which may contain pharmaceutically acceptable carriers, diluents and/or adjuvants.
- the pharmaceutical composition may be administered in the form of a tablet, capsule, solution, suspension, aerosol, spray etc (e.g. nasal or throat spray), gel, plaster etc.
- the medicament may be administered according to any known means, wherein oral, pulmonal and intravenous administration is particularly preferred.
- the dose of the active ingredient depends on the type and the variety of disease and usually is in the range from 1 to 2000 mg/day, preferably in the range from 10 to 200 mg/day.
- the present application has applications in human and veterinary medicine, particularly in human medicine.
- Fig. 1 Neuroprotective effect of mefloquine in the functional model outlined in the methods section.
- Fig. 2 Neuroprotective effect of acetylmefloquine in the functional model outlined in the methods section.
- Fig. 3 Silver stained gels of fractions enriched with Mefloquine-based affinity reagent (M: markers; RE: raw extract; F1-2, flow throughs, proteins not binding to affinity beads; E1-3: proteins binding to affinity beads and recovered by elutions of varying stringency): the numbered bands were identified by mass spectrometry.
- M markers
- RE raw extract
- F1-2 flow throughs, proteins not binding to affinity beads
- E1-3 proteins binding to affinity beads and recovered by elutions of varying stringency
- the proteins in the specific mefloquine- associated fractions E1-3 are those with numbers 41-54: Beyond some structural and housekeeping proteins (e.g.
- tubulin isoforms tubulin isoforms
- mefloquine binding 45, 46 and 48
- names and gene bank accession numbers are given in the following table: MWapp is the apparent molecular weight, pi is measured isoelectric point on 2D gels; MW 03 I is the calculated molecular weight.
- Fig. 4 Structure of Nelfinavir-Sepharose 4B.
- Fig. 5 Neuroprotective effect of nelfinavir and saquinavir in the functional model outlined in the methods section at concentrations of each 1 ⁇ M.
- Fig. 6 Silver stained gels of fractions enriched with Nelfinavir/Saquinavir- based affinity reagent (1 ,2: raw extracts; 3-9, flow throughs, unspecific elutions, proteins not related to nelfinavir-part of affinity material beads;
- 10,11 proteins binding to affinity beads and containing specific nelfinavir- related bands
- the numbered bands were identified by mass spectrometry.
- the proteins in the specific Nelfinavir/Saquinavir-associated fractions E1-3 are those with numbers 14-19: Beyond some structural and housekeeping proteins (e.g. tubulin isoforms), considered to be associated , but rather for anchoring than drug binding, the following bands appeared to be associated with Nelfinavir/Saquinavir binding: 14-10; names and gene bank accession numbers are given in the following table: MW ⁇ xp is the apparent molecular weight, pi is measured isoelectric point on
- the compounds are suitable as cytoprotective drugs and new lead structures for the development and optimization of related compounds with this novel mode of action, generally for cytoprotection and, particularly for the treatment of disorders of the nervous system related to underlying apoptotic and/or inflammatory mechanisms.
- ES cells D3 embryonic stem (ES) cells derived from 129/sv mice [Okabe et al., Mech. Dev. 59, 89-102 (1996)] were cultivated for 12 days, with passages on days 2, 4, 7 and 9 as described previously (Sommer S. et al., supra 2004). Insult conditions: Cells (24-well plates) were pre-incubated with or without 2OnM EPO in fresh medium for 24 hours at 37°C.
- Image resolution was 168 x 129 pixels (binning 8 x 8, pixel size 6.8 x 6.8 ⁇ m). Only cells identified as neurons by morphological criteria and occasional immunostaining (not shown) and those whose calcium levels returned to the resting state after the first stimulation were taken into account. Controls included nominal zero calcium (negative) and 5 ⁇ M ionomycin (positive), 10 ⁇ M glutamate (positive) and depolarisation (55 mM K + ) (positive). Pharmacological agents were applied by a multi-valve, single-output focal drug application device (ALA Scientific) with the perfusion system DAD-12. Ratio images were displayed as a percentage of relative change in fluorescence over background fluorescence scale for comparison across experiments (as described in Sommer S. et al., supra (2004)). During each stimulation event, 20 image pairs were acquired.
- ALA Scientific multi-valve, single-output focal drug application device
- mefloquine HCI 200 mg
- 10 ml of a 50% suspension of AffiGel 10 (BioRad) in isopropanol was added.
- the suspension was shaken at room temperature for 16 hours whereupon 0.3 ml of ethanolamine was added.
- beads were separated by filtration through glass sinter funnel and washed sequentially with 200 ml of DMF/isopropanol (1/1 ), 200 ml isopropanol, 200 ml 60% isopropanol, 500 ml 30% isopropanol and 1000 ml water.
- the obtained mefloquine-AffiGel 10 beads were kept as 50% slurry in 30% isopropanol at 4 0 C until used.
- the affinity beads (Meloquine-Affi-Gel 10) were used to bind the target(s) from fractionated crude cell extracts of D3 ES cells and other cell lines. Subsequently the affinity purified material was analysed by 1 D PAGE, immunostaining, and mass spectrometry.
- Monoclonal anti-PARP antibody was purchased from BD BioScience (Cat# 556 362; clone C2-10). Secondary anti-mouse alkaline phosphatase conjugate was purchased from Sigma (Cat# A9316).
- N BT/BC IP-western blot detection reagents came from Roche Diagnostics (Cat.# 1681451), Western Lightening CDP-Star chemiluminescence detection kit was supplied by Perkinelmer (Cat.# NEL616001 KT).
- proteins were separated on 10% polyacryl amide gels and blotted onto nitrocellulose.
- Blots were blocked with 5% skimmed milk powder in Tris buffered saline containing 0,1% Tween-20 (TBS-T).
- anti-PARP antibody was incubated over night at 4°C using a 1:1000 dilution in milk powder TBS-T. Blots were subsequently washed 3 times using TBS-T. A second antibody was used at a dilution of 1 :1000 for NBT/BCIP detection and 1 :5000 for CDP-Star detection.
- Cox-2 staining was obtained accordingly by using an antibody from Alexis, (ALX-210-711-1) anti-COX-2 (Cyclooxygenase-2); Rabbit, polyclonal; 1:1000 dilution; secondary antibody was anti-rabbit-AP (Sigma, A3937, 1 :1000)
- iNOS staining was performed using a polyclonal anti-iNOS, Alexis, 1 :1000). Blots were washed in TBS/1.0 % Tween and incubated with the appropriate secondary antibody-horseradish peroxidase conjugate (anti-rabbit IgG, Sigma, 1 :2000).
- CycLex® Sir2 Assay kit (Cat# CY- 1151) was used according to instructions of the manufacturer (CycLex Co., Ltd. 1063-103 Ohara, Tera-Sawaoka Ina, Nagano 396-0002 Japan). All substances tested in the SIR assay have to be cross-checked for their influence on the lysyl-endopeptidase. For this control an already deacetylated substrate peptide is used in order to measure directly lysyl- endopeptidase activity.
- LPS challenge of 3T3 fibroblasts A 549 cells, V56 embryonic stem cells and neurally differentiated V56 embryonic stem cells was equally performed by exposing cells to 100 ng/ml lipopolysaccharide (LPS, E.coli 0111 :B4 LPS from Sigma) for 60 min in the presence or absence of mefloquine and related compounds. Cell pellets were further investigated by Western blot staining with anti cox-2 and anti iNOS antibodies of 1D polyacrylamide gels.
- LPS lipopolysaccharide
- PoIy-ADP ribosylated proteins were quantified from appropriate cellular protein extracts by Western blots using as primary antibody: Anti-poly(ADP- ribose); Antigen: mouse; Biomol, Cat Nr SA-216, Lot Nr. : P7482; and as secondary antibody: Anti mouse, AP; Sigma A 9316, Lot: 31 K 9205; both antibodies were used at 1 :2000 dilution.
- apoptosis inducing factor AIF
- mitochondria apoptosis inducing factor
- mitochondrial fractions the cellular material was fractionated into cytosolic, nuclear and mitochondrial fractions according to Arnoult et al. (Damien Arnoult, Philippe Parone, Jean- Claude Martinou, Bruno Antonsson, Jerome Estaquier, and Jean Claude Ameisen Mitochondrial release of apoptosis-inducing factor occurs downstream of cytochrome c release in response to several proapoptotic stimuli Journal of Cell Biology, Volume 159, Number 6, December 23, 2002 923-929).
- AIF apoptosis inducing factor
- Figure 1 shows the neuroprotective effect of mefloquine in the functional model outlined in the methods section and Figure 2 those of its derivative acetylmefloquine. Whereas control cells had a survival rate of 28.3 + 1.8%, mefloquine-treated cells had survival rates ranging from of 47.1 to 61.3 % with an EC50 of approx. 90 nM.
- Mefloquine was used as a starting structure for the synthesis of the affinity reagent, which was used to bind the targets from fractionated crude cell extracts of D3 embryonic stem cells. Subsequently the affinity purified material was analysed by 1D PAGE ( Figure 3) and mass spectrometry. MALDI-TOF analysis of the silver stained gels indicated the presence of VDAC-1 , REA and prohibitin in enriched fractions.
- VDAC-1 Homo sapiens prohibitin
- PHB Homo sapiens prohibitin
- VDAC-1 Homo sapiens voltage-dependent anion channel 1
- HDAC histone deactylases
- the cytoprotective properties of these and other related compounds are rather due to a hitherto unknown dual mode of action namely VDAC-1 and REA.
- This novel mixed type of activity can be used for new high throughput screening of existing chemical libraries for identification of novel cytoprotective agents for the treatment of various indications as outlined above.
- the invention relates to cytoprotective properties of compounds with a VDAC-1 modulating activity. 3. Cox-2 and iNOS expression in LPS challenge and chemical ischemia of neuronal and non-neuronal cells
- a further preferred indication is for the prevention or treatment of inflammatory or inflammation-associated ocular disorders, particularly macula degeneration, e.g. moist or dry macula degeneration, glaucoma, e.g. acute, primary, secondary or low angle glaucoma, diabetic retinopathy, anterior or posterior optical neuropathy, retinitis pigmentosa, neuritis nervi optici, or central artery obstruction.
- macula degeneration e.g. moist or dry macula degeneration
- glaucoma e.g. acute, primary, secondary or low angle glaucoma
- diabetic retinopathy e.g. acute, primary, secondary or low angle glaucoma
- anterior or posterior optical neuropathy retinitis pigmentosa
- neuritis nervi optici e.g., central artery obstruction.
- nelfinavir, saquinavir and related compounds have a previously unknown and neuroprotective mode of action via binding to VDAC-1 , REA and prohibitin. Due to these previously unknown neuroprotective effects, the compounds are suitable as cytoprotective drugs and new lead structures for the development and optimization of related compounds with this novel mode of action, generally for cytoprotection and, particularly for the treatment of disorders of the nervous system related to underlying apoptotic and/or inflammatory mechanisms.
- D3 embryonic stem (ES) cells derived from 129/sv mice [Okabe et al., 1996, supra] were cultivated for 12 days, with passages on days 2, 4, 7 and 9 as described previously (Sommer S. et al., supra 2004).
- Insult conditions Cells (24-well plates) were pre-incubated with or without 2OnM EPO in fresh medium for 24 hours at 37°C. Cells were rinsed once with low K + solution (140 mM NaCI 1 4.7 mM KCI, 1.2 mM KH 2 PO 4 , 2.5 mM CaCI 2 , 1.2 mM MgSO 4 , 11 mM glucose, 15 mM Hepes-NaOH, pH 7.35).
- Excitation wavelengths ( ⁇ i, ⁇ 2 ) and the emission wavelength were 340, 380 and 510 nm, respectively. Acquisition and analysis of data after appropriate stimulation were performed by using MetaFluor software (Universal Imaging Corporation). Image resolution was 168 x 129 pixels (binning 8 x 8, pixel size 6.8 x 6.8 ⁇ m). Only cells identified as neurons by morphological criteria and occasional immunostaining (not shown) and those whose calcium levels returned to the resting state after the first stimulation were taken into account. Controls included nominal zero calcium (negative) and 5 ⁇ M ionomycin (positive), 10 ⁇ M glutamate (positive) and depolarisation (55 mM K + ) (positive).
- Pharmacological agents were applied by a multi-valve, single-output focal drug application device (ALA Scientific) with the perfusion system DAD-12. Ratio images were displayed as a percentage of relative change in fluorescence over background fluorescence scale for comparison across experiments (as described in Sommer S. et al., supra (2004)). During each stimulation event, 20 image pairs were acquired.
- ALA Scientific multi-valve, single-output focal drug application device
- nelfinavir free base or saquinavir
- 20 ml of 90% DMF 200 ⁇ l of ethyldiisopropylamine was added.
- the solution was cooled on ice.
- This solution was mixed with a suspension of 5 g sucked dried p-diazoniumbenzoylamido Sepharose 4B and shaked for 2 hours at room temperature. Then 0.2 ml of aniline was added and shaking was continued for another 60 min.
- Nelfinavir Sepharose 4B was separated by filtration and washed with 80% DMF (200 ml), 40% DMF (200 ml), water (200 ml), 0.1 M HCI (200 ml) water 500 ml. Finally it was resuspended in 30% 2-propanol and kept in fridge until used.
- Nelfinavir-Sepharose 4B The structure of Nelfinavir-Sepharose 4B is depicted in Figure 4.
- the affinity beads (nelfinavir/saquinavir-Affi-Gel 10) were used to bind the target(s) from fractionated crude cell extracts of D3 ES cells and other cell lines. Subsequently the affinity purified material was analysed by 1 D PAGE, immunostaining, and mass spectrometry.
- NBT/BCIP-westemblot detection reagents came from Roche Diagnostics (Cat.# 1681451)
- Western Lightening CDP-Star chemiluminescence detection kit was supplied by Perkinelmer (Cat.# NEL616001 KT).
- Perkinelmer Cat.# NEL616001 KT
- proteins were separated on 10% polyacryl amide gels and blotted onto nitrocellulose. Blots were blocked with 5% skimmed milk powder in Tris buffered saline containing 0,1% Tween-20 (TBS-T).
- anti-PARP antibody was incubated over night at 4 0 C using a 1 :1000 dilution in milk powder TBS-T. Blots were subsequently washed 3 times using TBS-T. A second antibody was used at a dilution of 1:1000 for NBT/BCIP detection and 1 :5000 for CDP-Star detection.
- Cox-2 staining was obtained accordingly by using an antibody from Alexis, (ALX-210-711-1) anti-COX-2 (Cyclooxygenase-2); Rabbit, polyclonal; 1 :1000 dilution; secondary antibody was anti-rabbit-AP (Sigma, A3937, 1 :1000).
- iNOS staining was performed using a polyclonal anti-iNOS, Alexis, 1 :1000). Blots were washed in TBS/1.0 % Tween and incubated with the appropriate secondary antibody-horseradish peroxidase conjugate (anti-rabbit IgG, Sigma, 1 :2000).
- LPS challenge of 3T3 fibroblasts A 549 cells, V56 embryonic stem cells and neurally differentiated V56 embryonic stem cells was equally performed by exposing cells to 100 ng/ml lipopolysaccharide (LPS, E.coli 0111 :B4 LPS from Sigma) for 60 min in the presence or absence of nelfinavir or saquinavir and related compounds respectively. Cell pellets were further investigated by Western blot staining with anti cox-2 and anti iNOS antibodies of 1 D polyacrylamide gels.
- LPS lipopolysaccharide
- PoIy-ADP ribosylated proteins were quantified from appropriate cellular protein extracts by Western blots using as primary antibody: Anti-poly(ADP- ribose); Antigen: mouse; Biomol, Cat Nr SA-216, Lot Nr. : P7482; and as secondary antibody: Anti mouse, AP; Sigma A 9316, Lot: 31 K 9205; both antibodies were used at 1 :2000 dilution.
- apoptosis inducing factor AIF
- mitochondrial fractions were fractionated into cytosolic, nuclear and mitochondrial fractions according to Arnoult et al. (Damien Arnoult, Philippe Parone, Jean- Claude Martinou, Bruno Antonsson, Jerome Estaquier, and Jean Claude Ameisen Mitochondrial release of apoptosis-inducing factor occurs downstream of cytochrome c release in response to several proapoptotic stimuli Journal of Cell Biology, Volume 159, Number 6, December 23, 2002 923-929).
- AIF apoptosis inducing factor
- Figure 5 shows the neuroprotective effect of nelfinavir and saquinavir in the functional model outlined in the methods section at concentrations of each 1 ⁇ M.
- control cells here had a survival rate of 5.9 ⁇ 3.3%
- nelfinavir (1 ⁇ M)-treated cells had a survival rate of 91.0 + 3.8%
- saquinavir (1 ⁇ M)- treated cells had a survival rate of 59.5 % ⁇ 5.5%, with EC50 of approx. 100 nM (nelfinavir) and 950 nM (saquinavir) under ischemic conditions.
- Nelfinavir was used as a starting structure for the synthesis of the affinity reagent, which was used to bind the targets from fractionations of crude cell extracts of D3 embryonic stem cells. Subsequently the affinity purified material was analysed by 1 D PAGE (Fig. 6) and mass spectrometry. MALDI-TOF analysis of the silver stained gels indicated the presence of VDAC-1 in specifically enriched fractions.
- VDAC-1 Homo sapiens prohibitin
- PHB Homo sapiens prohibitin
- VDAC-1 Homo sapiens voltage-dependent anion channel 1
- the cytoprotective properties of these and other related compounds are rather due to a hitherto unknown second mode of action on namely VDAC-1.
- This novel mixed type of activity can be used for new high throughput screening of existing chemical libraries for identification of novel cytoprotective agents for the treatment of various indications as outlined above.
- the invention relates to cytoprotective properties of compounds with a VDAC-1 modulating activity.
- a further preferred indication is for the prevention or treatment of inflammatory or inflammation-associated ocular disorders, particularly macula degeneration, e.g. moist or dry macula degeneration, glaucoma, e.g. acute, primary, secondary or low angle glaucoma, diabetic retinopathy, anterior or posterior optical neuropathy, retinitis pigmentosa, neuritis nervi optici, or central artery obstruction.
- macula degeneration e.g. moist or dry macula degeneration
- glaucoma e.g. acute, primary, secondary or low angle glaucoma
- diabetic retinopathy e.g. acute, primary, secondary or low angle glaucoma
- anterior or posterior optical neuropathy retinitis pigmentosa
- neuritis nervi optici e.g. central artery obstruction.
- VDAC1 As a plasma membrane NADH-oxidoreductase. Biofactors. 2004;21(1-4):215-21
- estradiol prevents amyloid-beta peptide-induced cell death in a cholinergic cell line via modulation of a classical estrogen receptor. 49: Neuroscience. 2003;121 (4):917-26.
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
L'invention concerne généralement l'activité neuroprotectrice, antiapoptotique et anti-inflammatoire de la mefloquine, du nelfinavir et du saquinavir et de dérivés de ces derniers, basée sur les interactions découvertes récemment avec les récepteurs de la prohibitine et des oestrogènes et sur l'inhibition du canal anionique mitochondrial voltage dépendant 1. On peut par conséquent utiliser la mefloquine, le nelfinavir et le saquinavir et les dérivés de ces derniers comme médicaments dans la prévention et/ou le traitement de maladies neurodégénératives et inflammatoires et, en particulier, de maladies neuroinflammatoires.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US67064805P | 2005-04-13 | 2005-04-13 | |
US60/670,648 | 2005-04-13 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2006108666A1 true WO2006108666A1 (fr) | 2006-10-19 |
Family
ID=36926305
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2006/003437 WO2006108666A1 (fr) | 2005-04-13 | 2006-04-13 | Mefloquine, nelfinavir et saquinavir utilises comme nouveaux agents dans les maladies neurodegeneratives et (neuro)inflammatoires |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2006108666A1 (fr) |
Cited By (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2010007179A1 (fr) * | 2008-07-18 | 2010-01-21 | Centre National De La Recherche Scientifique (Cnrs) | Derives heterocycliques utiles dans le traitement de maladies neurodegeneratives |
WO2011037467A1 (fr) * | 2009-09-28 | 2011-03-31 | Stichting Katholieke Universiteit | Atazanavir pour le traitement de maladies inflammatoires |
US7932268B2 (en) | 2004-03-05 | 2011-04-26 | The Trustees Of The University Of Pennsylvania | Methods for treating disorders or diseases associated with hyperlipidemia and hypercholesterolemia while minimizing side effects |
US8114892B2 (en) | 2006-02-16 | 2012-02-14 | The Mclean Hospital Corporation | Methods and compositions for the treatment of Parkinson's Disease |
WO2012088305A1 (fr) * | 2010-12-22 | 2012-06-28 | The Feinstein Institute For Medical Research | Procédés pour traiter le lupus érythémateux disséminé utilisant des inhibiteurs de protéase du vih |
CN103961684A (zh) * | 2014-05-23 | 2014-08-06 | 滨州医学院 | 沙奎拉韦在制备预防或治疗急性肺损伤/急性呼吸窘迫综合征和肺纤维化的药物中的应用 |
CN103977005A (zh) * | 2014-05-23 | 2014-08-13 | 滨州医学院 | 茚地那韦在制备预防或治疗急性肺损伤/急性呼吸窘迫综合征和肺纤维化的药物中的应用 |
CN103989689A (zh) * | 2014-05-28 | 2014-08-20 | 滨州医学院 | 地瑞那韦乙醇盐在制备预防或治疗急性肺损伤/急性呼吸窘迫综合征和肺纤维化的药物中的应用 |
CN104069104A (zh) * | 2014-07-03 | 2014-10-01 | 滨州医学院 | 利托那韦在制备预防或治疗急性肺损伤/急性呼吸窘迫综合征和肺纤维化的药物中的应用 |
CN104083373A (zh) * | 2014-07-08 | 2014-10-08 | 滨州医学院 | 洛匹那韦在制备预防或治疗急性肺损伤/急性呼吸窘迫综合征和肺纤维化的药物中的应用 |
WO2014187225A1 (fr) * | 2013-05-21 | 2014-11-27 | 华东师范大学 | Utilisation de méfloquine dans la préparation d'un médicament préventif contre la douleur neuropathique |
WO2014187226A1 (fr) * | 2013-05-21 | 2014-11-27 | 华东师范大学 | Utilisation de méfloquine lévogyre dans la préparation d'un médicament préventif contre la douleur neuropathique |
WO2017059122A1 (fr) * | 2015-09-29 | 2017-04-06 | The United States Of America, As Represented By The Secretary, Department Of Health And Human | Méthodes de traitement et de prévention d'une sclérose latérale amyotrophique |
WO2018081624A1 (fr) | 2016-10-27 | 2018-05-03 | The United States Government As Represented By The Department Of Veterans Affairs | Micro-arn dans l'activation de lymphocytes t |
RU2810301C2 (ru) * | 2022-04-08 | 2023-12-26 | федеральное государственное бюджетное образовательное учреждение высшего образования "Волгоградский государственный медицинский университет" Министерства здравоохранения Российской Федерации | Применение производного коричной кислоты при болезни Альцгеймера как церебропротекторного средства, регулирующего функцию VDAC1 |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6197788B1 (en) * | 1997-11-26 | 2001-03-06 | Vernalis Research Limited | (−)-mefloquine to block puringergic receptors and to treat movement or neurodegenerative disorders |
WO2002019994A2 (fr) * | 2000-09-05 | 2002-03-14 | Arakis Ltd. | Traitement de troubles inflammatoires |
WO2003051361A1 (fr) * | 2001-12-14 | 2003-06-26 | Cedars-Sinai Medical Center | Utilisation d'inhibiteurs de la protease du vih-1 et de leurs derives dans le traitement d'inflammations |
US20030216431A1 (en) * | 2002-05-17 | 2003-11-20 | Rajeev Raut | Ophthalmic pharmaceutical compositions and methods for treating ocular inflammation |
US20040220221A1 (en) * | 2002-01-17 | 2004-11-04 | Baker Helen Frances | Treatment of degenerative diseases |
US20050020580A1 (en) * | 2002-12-23 | 2005-01-27 | Badley Andrew D. | Materials and methods for the prevention or treatment of apoptosis and apoptosis-related diseases and conditions |
WO2005089762A2 (fr) * | 2004-03-17 | 2005-09-29 | Sosei R&D Ltd. | Composition pharmaceutique de (+)-erythro-mefloquine et son utilisation |
-
2006
- 2006-04-13 WO PCT/EP2006/003437 patent/WO2006108666A1/fr active Application Filing
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6197788B1 (en) * | 1997-11-26 | 2001-03-06 | Vernalis Research Limited | (−)-mefloquine to block puringergic receptors and to treat movement or neurodegenerative disorders |
WO2002019994A2 (fr) * | 2000-09-05 | 2002-03-14 | Arakis Ltd. | Traitement de troubles inflammatoires |
WO2003051361A1 (fr) * | 2001-12-14 | 2003-06-26 | Cedars-Sinai Medical Center | Utilisation d'inhibiteurs de la protease du vih-1 et de leurs derives dans le traitement d'inflammations |
US20040220221A1 (en) * | 2002-01-17 | 2004-11-04 | Baker Helen Frances | Treatment of degenerative diseases |
US20030216431A1 (en) * | 2002-05-17 | 2003-11-20 | Rajeev Raut | Ophthalmic pharmaceutical compositions and methods for treating ocular inflammation |
US20050020580A1 (en) * | 2002-12-23 | 2005-01-27 | Badley Andrew D. | Materials and methods for the prevention or treatment of apoptosis and apoptosis-related diseases and conditions |
WO2005089762A2 (fr) * | 2004-03-17 | 2005-09-29 | Sosei R&D Ltd. | Composition pharmaceutique de (+)-erythro-mefloquine et son utilisation |
Non-Patent Citations (2)
Title |
---|
CRUIKSHANK SCOTT J ET AL: "Potent block of Cx36 and Cx50 gap junction channels by mefloquine.", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA. 17 AUG 2004, vol. 101, no. 33, 17 August 2004 (2004-08-17), pages 12364 - 12369, XP002397598, ISSN: 0027-8424 * |
SHARMA AMITA ET AL: "Vi polysaccharide of Salmonella typhi targets the prohibitin family of molecules in intestinal epithelial cells and suppresses early inflammatory responses.", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA. 14 DEC 2004, vol. 101, no. 50, 14 December 2004 (2004-12-14), pages 17492 - 17497, XP002397599, ISSN: 0027-8424 * |
Cited By (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11554113B2 (en) | 2004-03-05 | 2023-01-17 | The Trustees Of The University Of Pennsylvania | Methods for treating disorders or diseases associated with hyperlipidemia and hypercholesterolemia while minimizing side-effects |
US9364470B2 (en) | 2004-03-05 | 2016-06-14 | The Trustees Of The University Of Pennsylvania | Methods for treating disorders or diseases associated with hyperlipidemia and hypercholesterolemia while minimizing side-effects |
US9433617B1 (en) | 2004-03-05 | 2016-09-06 | The Trustees Of The University Of Pennsylvania | Methods for treating disorders or diseases associated with hyperlipidemia and hypercholesterolemia while minimizing side-effects |
US7932268B2 (en) | 2004-03-05 | 2011-04-26 | The Trustees Of The University Of Pennsylvania | Methods for treating disorders or diseases associated with hyperlipidemia and hypercholesterolemia while minimizing side effects |
US9265758B2 (en) | 2004-03-05 | 2016-02-23 | The Trustees Of The University Of Pennsylvania | Methods for treating disorders or diseases associated with hyperlipidemia and hypercholesterolemia while minimizing side-effects |
US9861622B2 (en) | 2004-03-05 | 2018-01-09 | The Trustees Of The University Of Pennsylvania | Methods for treating disorders or diseases associated with hyperlipidemia and hypercholesterolemia while minimizing side-effects |
US10016404B2 (en) | 2004-03-05 | 2018-07-10 | The Trustees Of The University Of Pennsylvania | Methods for treating disorders or diseases associated with hyperlipidemia and hypercholesterolemia while minimizing side effects |
US10555938B2 (en) | 2004-03-05 | 2020-02-11 | The Trustees Of The University Of Pennsylvania | Methods for treating disorders or diseases associated with hyperlipidemia and hypercholesterolemia while minimizing side effects |
US8618135B2 (en) | 2004-03-05 | 2013-12-31 | The Trustees Of The University Of Pennsylvania | Methods for treating disorders or diseases associated with hyperlipidemia and hypercholesterolemia while minimizing side effects |
US8114892B2 (en) | 2006-02-16 | 2012-02-14 | The Mclean Hospital Corporation | Methods and compositions for the treatment of Parkinson's Disease |
CN102099338A (zh) * | 2008-07-18 | 2011-06-15 | 国家科学研究中心 | 用于治疗神经退行性疾病的杂环衍生物 |
US8445511B2 (en) | 2008-07-18 | 2013-05-21 | Centre National de la Recherche Scientifique (SNRS) | Quinoline or quinoxaline derivatives for treating neurodegenerative diseases |
WO2010007179A1 (fr) * | 2008-07-18 | 2010-01-21 | Centre National De La Recherche Scientifique (Cnrs) | Derives heterocycliques utiles dans le traitement de maladies neurodegeneratives |
FR2933977A1 (fr) * | 2008-07-18 | 2010-01-22 | Centre Nat Rech Scient | Derives heterocycliques utiles dans le traitement des maladies neurodegeneratives |
WO2011037467A1 (fr) * | 2009-09-28 | 2011-03-31 | Stichting Katholieke Universiteit | Atazanavir pour le traitement de maladies inflammatoires |
JP2014501263A (ja) * | 2010-12-22 | 2014-01-20 | ザ・フェインスタイン・インスティチュート・フォー・メディカル・リサーチ | Hivプロテアーゼ阻害剤を用いて全身性エリテマトーデスを治療する方法 |
CN103347539A (zh) * | 2010-12-22 | 2013-10-09 | 范斯坦医药研究院 | 使用hiv蛋白酶抑制剂治疗系统性红斑狼疮的方法 |
WO2012088305A1 (fr) * | 2010-12-22 | 2012-06-28 | The Feinstein Institute For Medical Research | Procédés pour traiter le lupus érythémateux disséminé utilisant des inhibiteurs de protéase du vih |
WO2014187225A1 (fr) * | 2013-05-21 | 2014-11-27 | 华东师范大学 | Utilisation de méfloquine dans la préparation d'un médicament préventif contre la douleur neuropathique |
CN104173348B (zh) * | 2013-05-21 | 2017-10-31 | 华东师范大学 | 左旋甲氟喹在制备预防神经病理性疼痛药物中的应用 |
CN104173347A (zh) * | 2013-05-21 | 2014-12-03 | 华东师范大学 | 甲氟喹在制备预防神经病理性疼痛药物中的应用 |
CN104173347B (zh) * | 2013-05-21 | 2017-10-31 | 华东师范大学 | 甲氟喹在制备预防神经病理性疼痛药物中的应用 |
WO2014187226A1 (fr) * | 2013-05-21 | 2014-11-27 | 华东师范大学 | Utilisation de méfloquine lévogyre dans la préparation d'un médicament préventif contre la douleur neuropathique |
CN104173348A (zh) * | 2013-05-21 | 2014-12-03 | 华东师范大学 | 左旋甲氟喹在制备预防神经病理性疼痛药物中的应用 |
CN103961684B (zh) * | 2014-05-23 | 2016-05-18 | 滨州医学院 | 沙奎拉韦在制备预防或治疗肺纤维化的药物中的应用 |
CN103977005A (zh) * | 2014-05-23 | 2014-08-13 | 滨州医学院 | 茚地那韦在制备预防或治疗急性肺损伤/急性呼吸窘迫综合征和肺纤维化的药物中的应用 |
CN103961684A (zh) * | 2014-05-23 | 2014-08-06 | 滨州医学院 | 沙奎拉韦在制备预防或治疗急性肺损伤/急性呼吸窘迫综合征和肺纤维化的药物中的应用 |
CN103989689A (zh) * | 2014-05-28 | 2014-08-20 | 滨州医学院 | 地瑞那韦乙醇盐在制备预防或治疗急性肺损伤/急性呼吸窘迫综合征和肺纤维化的药物中的应用 |
CN104069104A (zh) * | 2014-07-03 | 2014-10-01 | 滨州医学院 | 利托那韦在制备预防或治疗急性肺损伤/急性呼吸窘迫综合征和肺纤维化的药物中的应用 |
CN104083373A (zh) * | 2014-07-08 | 2014-10-08 | 滨州医学院 | 洛匹那韦在制备预防或治疗急性肺损伤/急性呼吸窘迫综合征和肺纤维化的药物中的应用 |
WO2017059122A1 (fr) * | 2015-09-29 | 2017-04-06 | The United States Of America, As Represented By The Secretary, Department Of Health And Human | Méthodes de traitement et de prévention d'une sclérose latérale amyotrophique |
WO2018081624A1 (fr) | 2016-10-27 | 2018-05-03 | The United States Government As Represented By The Department Of Veterans Affairs | Micro-arn dans l'activation de lymphocytes t |
RU2810301C2 (ru) * | 2022-04-08 | 2023-12-26 | федеральное государственное бюджетное образовательное учреждение высшего образования "Волгоградский государственный медицинский университет" Министерства здравоохранения Российской Федерации | Применение производного коричной кислоты при болезни Альцгеймера как церебропротекторного средства, регулирующего функцию VDAC1 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2006108666A1 (fr) | Mefloquine, nelfinavir et saquinavir utilises comme nouveaux agents dans les maladies neurodegeneratives et (neuro)inflammatoires | |
EP2970248B1 (fr) | Dérivés de coumarine et leurs méthodes d'utilisation dans le traitement de la fibrose kystique, de la bronchopneumopathie chronique obstructive et des troubles liés à des protéines mal repliées | |
Jiang et al. | Discovery of second-generation NLRP3 inflammasome inhibitors: Design, synthesis, and biological characterization | |
CN110869378B (zh) | 预防和治疗疾病的化合物及其用途 | |
KR20210144827A (ko) | 안드로겐 수용체의 억제제를 포함하는 약제학적 조성물 및 조합물 및 그의 용도 | |
US7919485B2 (en) | Protein kinase targeted therapeutics | |
US9645139B2 (en) | Neuroprotective chemicals and methods for identifying and using same | |
WO2020198712A1 (fr) | Compositions et combinaisons pharmaceutiques comprenant des inhibiteurs du récepteur des androgènes et utilisations de celles-ci | |
EP3630125A2 (fr) | Composés sénolytiques | |
CN102143744B (zh) | 7,8-二羟基黄酮及其衍生物在制备治疗抑郁的药物中的用途 | |
US20140378403A1 (en) | Compounds For Reducing Drug Resistance And Uses Thereof | |
JP6821701B2 (ja) | N−[2−(3−ヒドロキシ−3−メチルブチル)−6−(2−ヒドロキシプロパン−2−イル)−2h−インダゾール−5−イル]−6−(トリフルオロメチル)ピリジン−2−カルボキサミドの結晶形態 | |
KR20030061783A (ko) | 선택적 안드로겐 수용체 조절제 및 이들의 사용 방법 | |
JP2019502681A (ja) | 電位作動型ナトリウムチャネルにおいて選択的活性を有する、ヒドロキシアルキルアミンおよびヒドロキシシクロアルキルアミンで置換されたジアミン−アリールスルホンアミド化合物 | |
JP2006506369A (ja) | メチレン架橋選択的アンドロゲン受容体調節剤及びその使用方法 | |
US20170007588A1 (en) | Small molecule inhibitors of xbp1 splicing | |
CN115701991A (zh) | 吡唑基丙酰胺化合物及其用于治疗前列腺癌的用途 | |
CN113784709B (zh) | 用于治疗炎症性病症的化合物和方法 | |
KR20210027382A (ko) | 접히지 않은 단백질 반응의 활성화제 | |
WO2018006801A1 (fr) | Ligand du récepteur nucléaire orphelin nur77 et son application | |
JP2022541780A (ja) | Nlrp3インフラマソーム阻害剤としての化合物と組成物とその使用 | |
JP2019513762A (ja) | 胆汁うっ滞及び線維症の処置方法 | |
CN108848668B (zh) | Cftr调节剂及其使用方法 | |
Gonçalves et al. | Effect of N-1 arylation of monastrol on kinesin Eg5 inhibition in glioma cell lines | |
TW201906816A (zh) | 吲哚甲醯胺類衍生物、其製備方法及其在醫藥上的應用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWW | Wipo information: withdrawn in national office |
Country of ref document: DE |
|
NENP | Non-entry into the national phase |
Ref country code: RU |
|
WWW | Wipo information: withdrawn in national office |
Country of ref document: RU |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 06724326 Country of ref document: EP Kind code of ref document: A1 |